US20090123493A1 - Composition Comprising a Colloidal Synthetic Bioresorbable Vector and a Viral Vector - Google Patents
Composition Comprising a Colloidal Synthetic Bioresorbable Vector and a Viral Vector Download PDFInfo
- Publication number
- US20090123493A1 US20090123493A1 US12/084,970 US8497006A US2009123493A1 US 20090123493 A1 US20090123493 A1 US 20090123493A1 US 8497006 A US8497006 A US 8497006A US 2009123493 A1 US2009123493 A1 US 2009123493A1
- Authority
- US
- United States
- Prior art keywords
- mva
- pla
- protein
- vector
- gag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013598 vector Substances 0.000 title claims abstract description 94
- 239000013603 viral vector Substances 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims description 160
- 239000000126 substance Substances 0.000 claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 37
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 133
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 129
- 102000004169 proteins and genes Human genes 0.000 claims description 114
- 229960005486 vaccine Drugs 0.000 claims description 79
- 108091007433 antigens Proteins 0.000 claims description 27
- 102000036639 antigens Human genes 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 26
- 241000701161 unidentified adenovirus Species 0.000 claims description 23
- 230000003612 virological effect Effects 0.000 claims description 23
- -1 poly(α-hydroxy acids) Polymers 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 238000002255 vaccination Methods 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 229920005615 natural polymer Polymers 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 187
- 101710205625 Capsid protein p24 Proteins 0.000 description 187
- 101710177166 Phosphoprotein Proteins 0.000 description 187
- 101710149279 Small delta antigen Proteins 0.000 description 187
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 187
- 229920000747 poly(lactic acid) Polymers 0.000 description 173
- 239000004626 polylactic acid Substances 0.000 description 170
- 230000004044 response Effects 0.000 description 118
- 241000699670 Mus sp. Species 0.000 description 81
- 238000002347 injection Methods 0.000 description 68
- 239000007924 injection Substances 0.000 description 68
- 108010074328 Interferon-gamma Proteins 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 50
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 49
- 238000002649 immunization Methods 0.000 description 49
- 102100037850 Interferon gamma Human genes 0.000 description 47
- 230000028327 secretion Effects 0.000 description 44
- 238000002474 experimental method Methods 0.000 description 40
- 102000004127 Cytokines Human genes 0.000 description 37
- 108090000695 Cytokines Proteins 0.000 description 37
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 241000700605 Viruses Species 0.000 description 36
- 108010005774 beta-Galactosidase Proteins 0.000 description 36
- 230000008348 humoral response Effects 0.000 description 31
- 102000004388 Interleukin-4 Human genes 0.000 description 28
- 108090000978 Interleukin-4 Proteins 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 28
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 27
- 239000011859 microparticle Substances 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 22
- 229940037003 alum Drugs 0.000 description 22
- 230000028993 immune response Effects 0.000 description 22
- 241001135569 Human adenovirus 5 Species 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 108010002350 Interleukin-2 Proteins 0.000 description 16
- 102000000588 Interleukin-2 Human genes 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 230000001900 immune effect Effects 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 230000003248 secreting effect Effects 0.000 description 13
- 108010002616 Interleukin-5 Proteins 0.000 description 12
- 102000000743 Interleukin-5 Human genes 0.000 description 12
- 230000036755 cellular response Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 102000003814 Interleukin-10 Human genes 0.000 description 11
- 108090000174 Interleukin-10 Proteins 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000002238 attenuated effect Effects 0.000 description 8
- 238000007918 intramuscular administration Methods 0.000 description 8
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 7
- 241000711549 Hepacivirus C Species 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 241000700618 Vaccinia virus Species 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 108700004026 gag Genes Proteins 0.000 description 6
- 101150098622 gag gene Proteins 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 102100034349 Integrase Human genes 0.000 description 5
- 101710172711 Structural protein Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 4
- 101710149951 Protein Tat Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101710177291 Gag polyprotein Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical class C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 108091061960 Naked DNA Proteins 0.000 description 3
- 101710150344 Protein Rev Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000007402 cytotoxic response Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- 101710142585 50S ribosomal protein 6, chloroplastic Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710192141 Protein Nef Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000003263 anti-adenoviral effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000118 poly(D-lactic acid) Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150104494 CAV1 gene Proteins 0.000 description 1
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101150047856 Cav2 gene Proteins 0.000 description 1
- 241000919811 Collyria Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000761557 Lamina Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101100398282 Mus musculus Kit gene Proteins 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 101710174009 Suppressor of RNA silencing p3 Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000007414 peripheral immune response Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to the field of prophylactic and therapeutic vaccination.
- the present invention relates to a vaccine composition comprising a viral vector enabling expression of protein substances and a synthetic vector having protein substances.
- the antigens used in the vaccines are either living microorganisms, the pathogenic power of which has been attenuated, or killed microorganisms.
- these vaccines often cause undesirable secondary effects during administration and in rare cases they cause very serious complications.
- Such an immunogen, administered alone, can sometimes not induce a sufficient immune response.
- numerous vaccine strategies have been developed in order to increase or orient the immune response induced by the purified immunogens present in a vaccine.
- alum aluminium hydroxides
- alum is a weak adjuvant for inducing humoral responses, it is not appropriate for all antigens and does not enable cell responses to be obtained.
- the adjuvant currently being developed the most effective systems for inducing strong immunity are synthetic vectors based on microparticles and in particular microparticles of polylactic-co-glycolic acid (PLGA) and polylactic acid (PLA).
- the protein substance can be either encapsulated in the microparticles or adsorbed on the surface.
- the two approaches make it possible to induce both cellular and humoral immune responses, even if they were originally used above all in order to obtain an antibody response.
- encapsulation has two major drawbacks. The first is that a partial or total degradation of the microparticles is required for the protein substance to become available to the immune system, also the establishment of immunity is delayed. The second drawback is that the protein substance can be denatured or degraded during encapsulation and thus can lose its immunogenic properties.
- Recombinant viral vectors enable expression in vivo (in animals or in humans) of the relevant protein substance. This is an effective strategy which enables good mobilisation of the immune system.
- the induction of a lasting immune response necessitates the use of attenuated living vectors which can replicate in the vaccinated organism.
- new generations of vaccines use viral vectors which are non-replicative in humans, resulting in a diminution of the specific immune responses in time.
- prophylactic vaccines it is still sometimes necessary to restimulate the specific immunity in order to maintain an effective memory response.
- restimulation of the specific immunity remains useful for maintaining the intensity of the immune responses which enable control of the pathogenic organism.
- the repeated administration of viral vectors appears necessary but is accompanied by a major problem which is the problem of anti-vector immunity.
- the viral vector is itself an immunogen and as it is administered several times the specific immunity of the vector appears and then increases. This immune response is intended to eliminate the viral vector and also prevents the expression of the gene which it carries, thus resulting in a decrease in the effectiveness of the immune responses against the relevant protein substance.
- the anti-vector immunity prevents the use of the vector in question for vaccination against another disease.
- Schagen et al describe certain approaches which make it possible to alleviate this anti-vector immunity, such as modifications at the level of the vector or even adaptations at the level of the vaccinated patients (2004, Critical Reviews in Oncology/Hematology 50:51-70). However, the implementation of these approaches is difficult and cannot be achieved for all diseases or all patients. Therefore the strategy which uses viral vectors is not optimised.
- Another way of improving the immune response induced by vaccination is the prime-boost strategy. It consists of increasing the specific immune responses by administering sequentially two different vaccines which carry one and the same protein substance instead of administering the same vaccine several times. For example, it is possible to use a different viral vector at each injection (Negri D R, et al, 2004, Journal of General Virology, 85: 1191-1201). However, this strategy only has a few chances of success because the number of viral vectors which are authorised for use in humans is very restricted. Moreover, the repeated administration of these viral vectors again encounters the problem of anti-vector immunity.
- Otten et al describe the use of a DNA prime followed by a boost of PLGA microparticles with protein antigens adsorbed on the surface thereof (2003, Journal of Virology, 77: 6087-6092).
- Sharpe et al proposed a DNA prime encapsulating DNA in PLGA-based microparticles and a boost by a viral vector MVA (2003, Virology, 313: 13-21).
- O'Hagan et al describe the use of a prime by the DNA adsorbed on PLGA microparticles, followed by a boost by a vaccine vector (2001, Journal of Virology, 75: 9037-9043).
- Patent Application WO98/56919A describes a DNA prime followed by a boost by a poxvirus.
- the drawback of the use of a DNA prime is its low effectiveness particularly in primates and also when the gene is not very immunogenic such as for example the HIV-1 Tat gene.
- Patent Application WO98/56919A also describes the use of a prime by VLPs (virus-like particles), followed by a boost by a poxvirus.
- the VLPs are defective viral particles which do not incorporate the viral genome and which cannot reproduce.
- VLPs are often formed by self-assembly of the structural proteins of a virus or of a retrotransposon (endogenous element similar to a retrovirus) such as the precursor Pr55 Gag of HIV-1 or the proteins L1 and L2 of HPV-16 (human papilloma virus).
- a retrotransposon endogenous element similar to a retrovirus
- the structure of the VLP may be close to or less than that of the native virion, such that the VPLs are comparable to a virus.
- the drawback of these VLPs is that that they are the result of biotechnology and that their manufacture according to the statutory standards is very difficult.
- a first object of the invention consists of a pharmaceutical composition comprising or consisting of:
- Another object of the invention consists of the use of the said composition for the preparation of a medicament, preferably a vaccine. It can also be used for the in vitro diagnosis of pathological states relating to the protein substances of the composition according to the invention.
- the present invention therefore proposes a novel composition comprising a colloidal synthetic bioresorbable vector having at least one protein substance.
- a bioresorbable compound is understood to be a compound which is not toxic, that is to say a compound of which the administration in the organism does not cause a lethal, disabling or inconvenient physiological or metabolic modification in day-to-day living, and which can be eliminated by natural means from the organism after administration.
- colloid and colloidal define any dispersion of a substance (dispersed phase) within an aqueous continuous phase of which at least one of the three dimensions is less than or equal to 10 ⁇ m and preferably less than or equal to 1 ⁇ m.
- An aqueous continuous phase is a phase of which the composition is principally water, such 30 as for example a buffer or a water-miscible water/organic solvent mixture.
- an aqueous continuous phase appropriate to the purposes of the invention is a non-toxic phase.
- the disperse phase can be a liquid which is insoluble in the continuous phase such as for example an oil or a mixture of oils, or organic fatty materials, or it can even be a polymeric or mineral solid.
- the disperse phase is always bioresorbable.
- disperse phase examples include olive oil, sunflower oil, groundnut oil, rapeseed oil, or mixtures thereof; triglycerides; synthetic polymers such as polymers of hydroxyacid such as for example lactic acid, glycolic acid, hydroxybutyric acid, or compounds resulting from caprolactone; polypeptides such as the compounds resulting from caprolactone polymerisation; natural polymers such as for example polysaccharides such as hyaluronic acid, chitosan, or dextran.
- synthetic polymers such as polymers of hydroxyacid such as for example lactic acid, glycolic acid, hydroxybutyric acid, or compounds resulting from caprolactone
- polypeptides such as the compounds resulting from caprolactone polymerisation
- natural polymers such as for example polysaccharides such as hyaluronic acid, chitosan, or dextran.
- bioresorbable colloids examples include Benita A. and Levy M. Y., 1993, Journal of Pharmaceutical Sciences, 82(11): 1069-1079 (liquid/liquid emulsions), Trotta M., et al, 2003, International Journal of Pharmaceutics, 257: 152-160 (lipid solid/liquid emulsions), and Jiang W., et al, 2005, Biodegradable poly(lactic-co-glycolic) acid microparticles for injectable delivery of vaccine antigens Advanced Drug Delivery Reviews, 57: 391, 410.
- the form of the colloidal synthetic vector is given by the disperse phase which may or may not be spherical, which may be homogeneous or may be constituted by a stack of laminas.
- the synthetic vector according to the invention is preferably of spherical nature. Even more preferably the vector is composed of microspheres.
- microsphere and microparticle are used indiscriminately in the following description.
- a microparticle or microsphere is understood to mean a particle of a size at most in the micron range to enable them to enter the antigen presenting cells.
- a size at most in the micron range is understood to be a dimension smaller than or equal to 999 ⁇ m.
- Microparticles preferably have a particle diameter smaller than or equal to 3 ⁇ m. Even more preferably the particles according to the invention have a submicron size, preferably with a diameter between 150 and 900 nm, more preferably between 250 and 700 nm.
- the size of the particles is easily determined by techniques known to the person skilled in the art such as, for example, by using scanning electron microscopy, quasi-elastic scattering of light or transmission electron microscopy.
- colloidal synthetic vectors are polymer-based vectors.
- vectors comprising microparticles based on polymers such as poly( ⁇ -hydroxy acids), polyhydroxybutyric acids, polycaprolactones, polyorthoesters and polyanhydrides.
- the synthetic vector preferably comprises at least one bioresorbable polymer chosen from amongst a poly( ⁇ -hydroxy acid) such as poly(D-lactic acid), poly(L-lactic acid) (both known as PLA), polyglycolic acid (known as PLG), or a mixture of poly( ⁇ -hydroxy acids) such as a mixture of poly(D- and L-lactic acids), a mixture of poly(L-lactic acid) and polyglycolic acid, a mixture of poly(D-lactic acid) and polyglycolic acid, or a mixture of poly(D- and L-lactic acids) and polyglycolic acid.
- a poly( ⁇ -hydroxy acid) such as poly(D-lactic acid), poly(L-lactic acid) (both known as PLA), polyglycolic acid (known as PLG), or a mixture of poly( ⁇ -hydroxy acids) such as a mixture of poly(D- and L-lactic acids), a mixture of poly(L-lactic acid) and polyglycolic acid, a mixture of poly(D-lactic acid
- the colloidal synthetic vector according to the invention is preferably prepared from at least one polymer chosen from amongst the poly( ⁇ -hydroxy acids). More preferably, the particles according to the invention are free of stabiliser and surfactant so that they are not toxic.
- a toxic microparticle is understood to be a microparticle including at least one compound capable of causing biological problems, such as disturbances of the metabolism, in the organism which has received the microparticle.
- Such non-toxic particles can be prepared according to the protocol described in Patent Application WO2005/027871.
- the colloidal synthetic vector is prepared from at least one natural polymer such as those referred to above
- composition according to the invention is useful for stimulating both a cell-mediated response and a humoral response. It is useful both in prophylaxis and therapy and in diagnosis.
- protein substances which are useful for the purposes of the invention and are carried by the synthetic vector can be any protein substances against which an immune response is to be triggered.
- An immune response is understood to be a cell-mediated response, a humoral response or both.
- a cell-mediated response is understood to be a response mediated by the T-lymphocytes and/or other leucocytes. This response is reflected in the induction of a lytic activity by the cytotoxic T lymphocytes and/or by the production of cytokines by the CD8+ T lymphocytes or by the helper T cells.
- a humoral response is understood to be a response mediated by the antibody molecules secreted by the B lymphocytes.
- a protein substance is understood to be any protein substance playing the role of antigen after addition to the vectors which are appropriate for the purposes of the invention such as peptides, proteins, protein fragments, polyproteins and glycoproteins, it being understood that the protein fragments have retained the relevant structure.
- Antigens are molecules capable of being recognised by an antibody of which they have induced the synthesis by an immune response and containing at least one epitope.
- protein fragments comprise for peptides, polypeptides and epitopes.
- Epitopes are peptides comprising between 3 and 15 and generally between 5 and 15 amino acids, consisting of the minimum peptide fragment against which an immune response is triggered.
- the synthetic vector has multiple copies of the protein substances.
- “At least one protein substance” is understood to mean at least several protein substances of the same type.
- “A type of protein substance” is understood to mean a set of protein substances which trigger the same immune response by production of the same antibodies (i.e. having the same immunity).
- the synthetic vector may therefore comprise:
- the synthetic vector comprises protein substances of different types and constituting antigens associated with the same disease.
- the protein substances may be of several origins such as viral or bacterial origin or of a pathology of non-infectious origin (such as cancer or a metabolic disease).
- the protein substance is an antigen of viral origin.
- the viruses used are all viruses for which substances capable of an immune response are known.
- herpes viruses such as hepatitis B virus (HBV) or hepatitis C virus (HCV), papilloma viruses (HPV), human immunodeficiency viruses (HIV), such as HIV-1 and HIV-2, different strains of the human influenza and avian influenza viruses.
- HBV hepatitis B virus
- HCV hepatitis C virus
- HPV papilloma viruses
- HIV human immunodeficiency viruses
- HIV-1 and HIV-2 different strains of the human influenza and avian influenza viruses.
- nucleic sequences of the viruses which are appropriate for the purposes of the invention, as well as the proteins coded by the said sequences are widely known to the person skilled in the art and are available for example in databases such as GenBank.
- the HIV virus has genes which code for structural proteins of the virus.
- the Gag gene codes for the protein which forms the core of the virion, including the p24 antigen.
- the Pol gene codes for the enzymes responsible for the reverse transcription (reverse transcriptase), cleavage (protease) and integration (integrase).
- the Env gene codes for envelope glycoproteins. It contains other genes (Tat, Rev, Nef, Vif, Vpr and Vpu (HIV-1) or Vpx (HIV-2) which code for proteins involved in the regulation of the expression of the genes of the virus (regulating proteins).
- the HIV genome also comprises the 5′ and 3′ LTRs (long terminal repeats) which comprise regulating elements involved in the expression of the genes of the virus.
- the protein substance used in the method according to the invention is a protein of the HIV virus.
- an antigen of the HIV virus mention may be made of regulating proteins or the Gag protein or the Env glycoprotein, the preferred regulating proteins being the Tat, Rev or Nef protein.
- the 5′ end of its genome corresponds to a non-translated region adjacent to the genes which code for the structural proteins, the core protein of the nucleocapsid, the two envelope glycoproteins, E1 and E2, and a small protein known as p7.
- the 5′ non-translated region and the core gene are relatively well preserved in the different genotypes.
- the envelope proteins E1 and E2 are coded by regions which are more variable from one isolate to another.
- the p7 protein is an extremely hydrophobic protein which would constitute an ion channel.
- the 3′ end of the HCV genome contains the genes which code for the non-structural proteins (NS2, NS3, NS4, NS5) and for a non-coding 3′ region having a well preserved domain (Major M E, Feinstone S M, Hepatology, June 1997, 25(6): 1527-1538).
- the non-structural protein NS3 of the HCV is a protein of 630 amino acids which comprises two distinct structural domains: an N-terminal domain of 81 amino acids, endowed with an active serine protease activity which intervenes in the maturation of the viral protein (domain called NS3 protease), and a C-terminal domain of 549 amino acids, comprising a helicase activity associated with an NTP ase activity which plays a part in the reproduction of the viral genome (domain called NS3 helicase).
- This protein NS3 is relatively well preserved amongst the different genotypes of the virus, such that this protein constitutes a “candidate vaccine” antigen of choice.
- the protein substance is an antigen associated with tumours.
- tumour-associated antigens TAA
- tumour markers Houghton AN, 1994, J Exp Med 180:10
- tumour line CT26.WT genetic base BALB/c
- the tumour line CT26.WT was transfected by the lacZ gene of Escherichia coli which codes for the enzyme beta-galactosidase in order to create the line CT26.CL25.
- the two lines are lethal in mice and their growth kinetics are similar.
- Administered in mice, the line CT26.CL25 is the origin of the formation of tumours which can be slowed down or indeed inhibited in the presence of an immune response against beta-galactosidase which constitutes a model TAA.
- the protein substances appropriate for the purposes of the invention can be obtained by genetic engineering techniques which include the steps of:
- the relevant protein substances When the relevant protein substances are small in size, they can also be prepared by conventional peptide syntheses which are well known to the person skilled in the art.
- the protein substance is combined with the colloidal vectors according to techniques which are known to the person skilled in the art, such as inclusion or bonding on the surface.
- inclusion of the protein substance in the colloidal synthetic vector mention may be made of encapsulation (Tamber H. et al, 2005, Adv Drug Deliv Rev, 57(3); 357-76).
- bonding of the colloidal substance to the colloidal synthetic vector mention may be made of adsorption, as described in Patent Application WO2005/027871, or covalent grafting involving the formation of a chemical bond between a reactive group of the colloidal vector and another of the protein substance in a manner described for example in “Protein immobilization Fundamentals and Applications R. F. Taylor Ed, Marcel Dekker Inc., New York, 1991.
- the protein substances are added to the synthetic vectors by bonding and more preferably by adsorption, such as for example by mixing the microparticles with the protein substances and incubating them whilst stirring, for example at ambient temperature or at 37° C.
- composition according to the invention also comprises a viral vector.
- the viral vector comprises at least one nucleotide sequence which codes for a protein substance corresponding to at least one protein substance of the synthetic vector.
- Protein substance of the viral vector corresponding to at least one protein substance of the synthetic vector is understood to mean that the protein substance of the viral vector constitutes an antigen associated with the same disease as the protein substance of the synthetic vector, regardless of whether it is the same type or a different type, as indicated above.
- the protein substances are of a different type they must have at least one epitope in common, such as for example the Gag and p24 proteins.
- the genome of the viral vector is modified so as to insert one or several nucleotide sequences which code for one or several protein substances constituting antigens of the same disease or of different diseases.
- these protein substances at least one corresponds to a protein substance of the synthetic vector, these protein substances constituting antigens associated with the same disease.
- the viral vector comprises a nucleotide sequence which codes for a protein of HIV.
- the viral vector Apart from the nucleotide sequence or sequences coding for at least one protein substance constituting an antigen associated with the same disease as the protein substance of the synthetic vector, the viral vector also comprises the means necessary for the expression of the said protein substance.
- “Means necessary for the expression of a protein substance” are understood to mean any means which enable the protein substance to be obtained, such as in particular a promoter, a transcription terminator, an origin of replication and preferably a selection marker.
- operably linked is understood to mean a juxtaposition of the said elements necessary for expression and of the gene which codes for the protein substance, which are in a relation which enables them to function in the expected manner. For example, additional bases may exist between the promoter and the relevant gene as long as their functional relation is maintained.
- the means necessary for the expression of the protein substance may be homologous means, that is to say means included in the genome of the vector which is used, or they may be heterologous. In this latter case the said means are cloned with the relevant protein to be expressed.
- heterologous promoters comprise (i) viral promoters such as the promoter SV40 (simian virus 40), the promoter of the thymidine kinase gene of the herpes simplex virus (TK-HSV-1), the LTR of the Rous sarcoma virus (RSV), the intermediate early promoter of the human cytomegalovirus (CMV) and the adenoviral major late promoter (MLP), as well as (ii) any cellular promoter which controls the transcription of the genes which code for proteins in higher eukaryotes, such as the promoter of the constitutive phosphoglycerate kinase (PGK) gene (Adra et al, 1987, Gene, 60: 65-74), the promoter of the specific genes of liver alpha1-antitrypsin and FIX and the specific promoter SM22 of soft muscle cells (Moessler et al, 1996, Development, 122: 2415-2425).
- viral promoters such as the promoter
- the said sequences contained in the viral vector can be linked directly to one another under the control of one single promoter and/or one single expression regulating element, or they can be separated by each being dependent upon independent promoters and/or expression regulators which may be identical or different.
- viral vectors which are suitable for the purposes of the invention, mention may be made for example of the viral vectors of the adenovirus, poxvirus, baculovirus, herpes virus, togavirus, retrovirus type.
- Adenoviruses have been detected in numerous animal species. They do not integrate and are not very pathogenic. They are capable of infecting a variety of cell types, dividing cells and resting cells. They have a natural tropism for bronchial epitheliums. Moreover, they have been used as live enteric vaccines for a number of years with an excellent safety record. Finally, they can be easily grown and purified in large quantities. Due to these characteristics adenoviruses are particularly appropriate for use as expression vectors and in particular as gene therapy vectors for the purposes of therapy and vaccination.
- the vector according to the invention is an adenovirus.
- adenoviruses to be used in the present invention may be derived from any source of human or animal origin, in particular of canine origin (for example CAV-1 or CAV-2; GenBank reference CAVIGENOM and CAV77082 respectively), of avian origin (GenBank reference AAVEDSDNA), of bovine origin (such as BAV3, Seshidhar Reddy et al, 1998, J. Virol., 72:1394-1402), of ovine, feline or porcine origin, of simian origin, or one of their hybrids. Any serotype may be used. However, the adenoviruses of human origin are preferred and in particular the adenovirus 5 (Ad5).
- viruses referred to are available in the ATCC collections and have been the subject of numerous publications describing their sequences, their organisation and their biology, which enables the person skilled in the art to apply them easily.
- sequence of the adenovirus type 5 is described in the GenBank database (M73260 and M29978) and is incorporated herein by reference.
- the genome of adenoviruses consists of a linear double-strand DNA molecule of approximately 36 kb carrying more than approximately 30 genes necessary for terminating the viral cycle.
- the regions E1, E2 and E4 are essential for the viral replication.
- the region E3 is considered as a non-essential region based on the observation that mutant viruses appear naturally or hybrid viruses which have lost this region E3 continue to replicate like viruses of the wild type in cultured cells (Kelly and Lewis, 1973, J. Virol., 12: 643-652).
- the majority of late genes (L1 to L5) code for the structural proteins which form the viral capsid.
- the adenoviral genome carries at the two ends cis-action regions which are essential for the DNA replication respectively the inverted repeat motifs 5′ and 3′ (ITRs for “inverted terminal repeats”) and a packaging sequence.
- the adenoviruses currently used in the gene therapy protocols are devoid of the majority of region E1, which makes the viruses deficient at the replication level in order to prevent their dissemination in the environment and in the host organism. Moreover, the majority of adenoviruses are also devoid of region E3 in order to increase their cloning capacity.
- the feasibility of gene transfer using these vectors has been demonstrated in a variety of tissues in vivo (see for example Yei et al, 1994, Hum. Gen. Ther., 5: 731-744; Dai et al, 1995, Proc. Natl. Acad. Sci. USA, 92: 1401-1405; U.S. Pat. No. 6,099,831; and U.S. Pat. No. 6,013,638).
- Another expression vector which is particularly appropriate for the purposes of the invention is a poxvirus, which constitutes another embodiment of the invention.
- Poxviruses constitute a group of complex enveloped viruses which are distinguished principally by their unusual morphology, their large DNA genome and their cytoplasmic replication site.
- the genome of several elements of the poxyiridiae comprising the viral strain of the Copenhagen vaccinia (VV) (Goebel et al, 1990, Virol. 179: 247-266 and 517-563) and the strain of the Modified Vaccinia Virus Ankara (MVA) (Antoine et al, 1998, Virol., 244: 635-396), has been mapped and sequenced.
- the strain VV has a double-strand DNA genome of approximately 192 kb which codes for approximately 200 proteins of which approximately 100 are involved in the assembly of the virus.
- the strain MVA is a highly attenuated strain of the vaccinia virus, generated by more than 500 serial passages of the Ankara strain of the vaccinia virus (CVA) on chicken embryo fibroblasts (Mayr et al, 1975, Infection, 3: 6-16).
- the virus MVA has been deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) under the number 1-721.
- CNCM Collection Nationale de Cultures de Microorganismes
- the determination of the complete sequence of the genome of MVA and the comparison with that of VV enables precise identification of the alterations which have occurred in the viral genome and the definition of seven deletions (I to VII) and numerous mutations leading to fragmented open reading frames (Antoine et al, 1998, Virology, 244: 365-396).
- poxviruses which are appropriate for the purposes of the invention comprise canarypox, fowlpox, cowpox, entomopox, monkeypox, swinepox and penguinpox.
- Poxvirus occurs in two morphologically distinct forms, known as intracellular mature virus (IMV) and extracellular enveloped virus (EEV).
- the poxvirus used for the purposes of the invention is preferably a modified vaccinia virus Ankara.
- the methods of suppression and insertion of DNA sequences in expression vectors are widely known by the person skilled in the art and consist in particular of steps of enzymatic digestion and ligation.
- the nucleotide sequence inserted into the viral vector preferably codes for a protein of the HIV virus.
- compositions based on vectors according to the invention are particularly effective for inhibiting, preventing and treating a disease for which the protein substance of the composition constitutes an antigen, such as an infection by a virus. They are therefore particularly useful for the preparation of a medicament, in particular a vaccine, which may be therapeutic or prophylactic.
- the invention also relates to a method of prophylactic or therapeutic treatment, in particular vaccination, comprising the administration to a patient of an effective dose of the composition according to the invention.
- compositions according to the invention are appropriate for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal, rectal, vaginal, intraocular, intraauricular administration, and the said active principle can be administered in unitary administration form.
- the unitary administration forms may be for example tablets, capsules, granules, powders, injectable oral solutions or suspensions, transdermal patches, sublingual, buccal, intratracheal, intraocular, intranasal, intraauricular forms of administration, forms of administration by inhalation, topical forms of administration such as rectal or vaginal, transdermal, subcutaneous, intramuscular or intravenous forms of administration, or implants.
- topical administration creams, gels, ointments, lotions or collyria may be envisaged.
- the said unitary forms are dosed in order to enable daily administration of 0.001 to 10 mg of active principle per kg of body weight depending upon the Galenic form.
- the appropriate dosage for each patient is determined by the doctor according to the mode of administration, the weight and the response of the patient.
- excipient can be easily determined by the person skilled in the art. They are chosen as a function of the pharmaceutical form and the mode of administration which are required.
- composition according to the invention can be contained in a pharmaceutical kit.
- administration of the composition according to the invention may be simultaneous, separate or staggered.
- Simultaneous administration is understood to mean administration of the composition at the same time and at the same location.
- Staggered administration is understood to mean the administration of the viral vector or the synthetic vector at different times.
- the interval between each administration may extend from a few minutes to several years, preferably from several weeks to several months and more preferably it may be 3 or 4 weeks.
- Separate administration is understood to mean the administration of the viral vector and the synthetic vector at different locations on the body.
- the viral vector and the synthetic vector may be in the same excipient or preferably in appropriate different excipients.
- composition according to the invention is preferably administered in a staggered manner. More preferably the synthetic vector is administered before the viral vector.
- composition according to the invention comprises:
- the invention also has a diagnostic application.
- the invention also relates to the use of the composition according to the invention for the diagnosis in vitro of the pathological state for which the protein substance or substances of the synthetic vector and of the synthetic vector constitute antigens, and in particular of a viral infection or a cancer.
- FIG. 1 shows the CTL responses during the immunisation experiment No. 1 with different vaccine compositions including the compositions according to the invention which comprise a synthetic vector based on microparticles of poly(D,L-lactic acid) combined with protein p24 (referred to hereafter as PLA/p24) and a viral vector MVA comprising the Gag sequence (referred to hereafter as MVA Gag virus).
- compositions according to the invention which comprise a synthetic vector based on microparticles of poly(D,L-lactic acid) combined with protein p24 (referred to hereafter as PLA/p24) and a viral vector MVA comprising the Gag sequence (referred to hereafter as MVA Gag virus).
- FIG. 2 shows the specific ELISPOT IFN- ⁇ responses of the Gag AMQ peptide during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag.
- FIG. 3 shows the specific ELISPOT IFN- ⁇ responses of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag.
- FIG. 4 shows the specific ELISPOT IL-4 responses of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag.
- FIG. 5 shows the secretion of the specific cytokine GM-CSF of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag.
- FIG. 6 shows the secretion of the specific cytokine IL-5 of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag.
- FIG. 7 shows the secretion of the specific cytokine IL-2 of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag.
- FIG. 8 shows the appearance kinetics of the specific humoral responses of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag.
- FIG. 9 shows the CTL responses during the immunisation experiment No. 2 with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector Adenovirus Gag.
- FIG. 10 shows the specific ELISPOT IFN- ⁇ responses of the Gag AMQ peptide after immunisation with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector Adenovirus Gag.
- FIG. 11 shows the specific secretion of the protein p24 of the cytokines IL-2, IL-4, IL-10 after immunisation with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector Adenovirus Gag.
- FIG. 12 shows the appearance kinetics of the specific humoral responses of the protein p24 ( 12 A) or of the adenovirus ( 12 B) after immunisation with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector Adenovirus Gag.
- FIG. 13 compares the specific ELISPOT IFN- ⁇ responses of the peptide Gag AMQ after immunisation with different vaccine compositions including the compositions which comprise PLA/p24 and MVA Gag or comprise alum/p24 and MVA Gag.
- FIG. 14 compares the specific ELISPOT IL-4 responses of the protein p24 after immunisation with different vaccine compositions including the compositions which comprise PLA/p24 and MVA Gag or comprise alum/p24 and MVA Gag.
- FIG. 15 compares the appearance kinetics of the specific humoral responses of the protein p24 after immunisation with different vaccine compositions including the compositions which comprise PLA/p24 and MVA Gag or comprise alum/p24 and MVA Gag.
- FIG. 16 compares the appearance kinetics of the specific humoral responses of the MVA virus after immunisation with different vaccine compositions including the compositions which comprise PLA/p24 and MVA Gag or comprise alum/p24 and MVA Gag.
- FIG. 17 shows the specific ELISPOT IFN- ⁇ responses of the peptide beta-gal TPH after immunisation of mice with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA-beta-gal and the viral vector MVA beta-gal.
- FIG. 18 compares the appearance kinetics of the specific humoral responses of the beta-gal after immunisation of mice with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA-beta-gal and the viral vector MVA beta-gal.
- FIG. 19 shows the specific ELISPOT IFN- ⁇ responses of the peptide p24 AMQ after immunisation of mice with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector CPL-P24 and the viral vector MVA Gag.
- FIG. 20 compares the appearance kinetics of the specific humoral responses of the peptide p24 AMQ after immunisation of mice with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector CPL-P24 and the viral vector MVA Gag.
- the vaccine composition used comprises a synthetic vector based on microparticles of poly(D,L-lactic acid) combined with protein p24 (referred to hereafter as PLA/p24) and a viral vector MVA comprising the Gag sequence of SEQ ID No 1 (referred to hereafter as MVA Gag virus).
- the immunisation experiments were carried out in female BALB/c (H-2K d ) mice aged from 6 to 8 weeks at the time of the first immunisation.
- Gag DNA The Gag gene (from SEQ ID No. 1) was cloned in the eukaryotic expression plasmid phCMV (contains the intermediate/early promoter of the human cytomegalovirus and splicing and polyadenylation signals from the rabbit beta-globin gene (Y K Yee et al, 1994, Proc Natl Acad Sci USA, 91(20):9564-9568)). DNA preparations without endotoxins and in a large quantity have been produced using the Gigaprep endotoxin-free kit from Macherey-Nagel. The DNA serves as positive control, since it is known that in mice the intramuscular administration of naked DNA makes it possible to induce a good cytotoxic response (CTL).
- CTL cytotoxic response
- mice received 2 doses of the immunogens described in point 2 above at 0 and 3 weeks.
- the vaccine compositions received by each group of mice are indicated in Table 1 below. All the injections were carried out subcutaneously except for the DNA which was administered by the intramuscular route.
- the animals were sacrificed 6 weeks after the first injection and the blood and the spleen were removed for immunological analyses.
- mice received 2 or 3 doses of the immunogens described in point 2 above at 0, 3 and 6 weeks.
- the vaccine compositions received by each group of mice are indicated in Table 2 below. All the injections were carried out subcutaneously.
- mice MVA Gag 10 7 pfu MVA Gag 10 7 pfu 5 MVA Gag 10 7 pfu MVA Gag 10 7 pfu MVA Gag 10 7 pfu 5 MVA Gag 10 7 pfu PLA/p24 40 ⁇ g 5 MVA Gag 10 7 pfu PLA/p24 40 ⁇ g PLA/p24 40 ⁇ g 5 PLA/p24 40 ⁇ g MVA Gag 10 7 pfu 5 wild MVA 10 7 pfu wild MVA 10 7 pfu wild MVA 10 7 pfu wild MVA 10 7 pfu wild MVA 10 7 pfu 5 pfu 5
- the animals were sacrificed 3 weeks after the last injection and the blood and the spleen were removed for immunological analyses.
- mice received 2 or 3 doses of the immunogens described in point 2 above at 0, 3 and 6 weeks.
- the vaccine compositions received by each group of mice are indicated in Table 3 below. All the injections were carried out subcutaneously.
- the animals were sacrificed 3 weeks after the last injection and the blood and the spleen were removed for immunological analyses.
- the 96-well ELISPOT plates with PVDF membranes (Multiscreen IP, Millipore) were coated by an anti-IFN-? or anti-IL-4 antibody. During the restimulation the suspensions of splenocytes were incubated in these plates in such a way as to capture the cytokines secreted by each cell. The spots corresponding to each cell secreting the relevant cytokine were revealed by a specific biotinylated detection antibody of the relevant cytokine.
- cytokines secretion of cytokines: The splenocytes were stimulated for 3 days in complete culture medium (culture medium: alpha minimal essential medium ( ⁇ MEM) containing 10% foetal calf serum, 10 mM HEPES, 5 ⁇ 10 ⁇ 5 M ⁇ -mercaptoethanol, 4 nM L-glutamine, 80 U/ml penicillin, 80 mg/ml streptomycin, non-essential amino acids 1x (cat. no. 11140-035), sodium pyruvate 1x (cat no.
- ⁇ MEM alpha minimal essential medium
- penicillin penicillin
- streptomycin non-essential amino acids 1x
- non-essential amino acids 1x cat. no. 11140-035
- sodium pyruvate 1x cat no.
- FIG. 1 shows the CTL responses obtained during the immunisation experiment No. 1.
- Each group consists of 5 mice, the spleens were pooled before the CTL dosage was carried out. Since the non-specific stimulation (without peptide) in all the groups was 0, this is not shown. Likewise, since the CTL responses obtained with the compositions A, D and E were 0, they are not shown.
- the X axis corresponds to the ratio of effector cells (CTL) to target cells (to be lysed).
- the Y axis corresponds to the mean lysis percentage.
- the CTL responses induced are of low intensity with all the immunogens used (MVA, PLA or combinations), with the exception of the group G of Experiment I which received DNA last ( FIG. 1 ).
- the induction of CTL in the DNA groups is normal: the DNA is optimised for this purpose, it is a positive control in mice but does not work so well in primates.
- the gamma or type II interferon is also called immune interferon because it is secreted by the type CD4+ T lymphocytes, by the type CD8+ T lymphocytes and the NK cells. It protects the cells against viral infections. It stimulates the phagocytic activity of macrophages, enabling them to kill the tumour cells. It stimulates the maturation of the T and B lymphocytes and increases the production of antibodies. It increases the expression of class I and II HLA molecules by the macrophages. It is a type Th1 cytokine.
- composition MVA+MVA composition MVA+MVA
- PLA+MVA composition PLA+MVA
- composition PLA+MVA composition PLA+MVA
- the compositions MVA+PLA (B and B′) and DNA+PLA (F) enable intermediate intensity responses to be generated, whilst the strategy using only PLA (D and D′) only induces low responses
- the vaccine composition PLA+MVA (C) was at least as good as, if not better than the combination MVA+MVA (A) for inducing a secretion of specific IFN- ⁇ of the peptide AMQ.
- the third injection further decreases the response observed in the case of the composition PLA+MVA (C′).
- the compositions MVA+PLA (B and B′) and MVA+MVA (A and A′) enable intermediate intensity responses to be generated, whilst the strategy using only PLA (D and D′) only induces low responses
- PLA+MVA was the best choice for inducing a secretion of specific IFN- ⁇ of the protein p24.
- compositions are classified into several categories as a function of the ELISPOT IL-4 responses obtained.
- the best response is induced by the composition PLA+MVA (C and C′).
- the third injection does not seem necessary since it only slightly improves the response induced by the composition PLA+MVA (C′).
- the compositions MVA+PLA (B and B′) and DNA+PLA (F) and PLA+PLA (D and D′) enable intermediate intensity responses to be generated, whilst the strategy using only MVA only induces low responses (A and A′).
- PLA+MVA was the best choice for inducing a secretion of specific IL-4 of the protein p24.
- cytokines The study of the secretion of cytokines makes it possible to create a table of the state of immune activation of the animal which received the vaccine composition.
- the cytokines can be divided into four groups as a function of their properties:
- cytokines are: IFN- ⁇ , TNF- ⁇ , GM-CSF, IL-4, IL-17, IL-1 ⁇ , IL-2, IL-5, IL-6, IL-10.
- FIG. 5 shows the secretion of the specific cytokine GM-CSF of the protein p24. All the animals immunised during the 3 successive experiments were included in the analysis when the quantity of cells available permitted it. For each vaccine composition the number of animals which received this composition is indicated in brackets. The cells obtained from mice of one and the same group were pooled before being cultured for the secretion test. The Y axis shows the concentration of GM-CSF (in pg/ml) secreted in the culture medium in response to a stimulation for 3 days by the protein p24.
- the cytokine GM-CSF (granulocyte-macrophage colony stimulating factor) is a powerful immunostimulator which enables activation of the immune functions such as adhesion, phagocytosis, etc. of macrophages, neutrophiles and eosinophiles.
- FIG. 5 we have shown a substantial secretion of GN-CSF in the groups containing PLA in association or not with MVA (except for when the number of injections is increased to 3 for the PLAs) whilst the groups immunised exclusively with MVA secretes little or none of it.
- FIG. 6 shows the secretion of the cytokine IL-5 specific of the protein p24. All the animals immunised during the 3 successive experiments were included in the analysis when the quantity of cells available permitted it. For each vaccine composition the number of animals which received this composition is indicated in brackets. The cells obtained from mice of one and the same group were pooled before being cultured for the secretion test. The Y axis shows the concentration of IL-5 (in pg/ml) secreted in the culture medium in response to a stimulation for 3 days by the protein p 24.
- Th2 cytokines tested such as IL-4, IL-5, IL-6 and IL-10 the secretion profiles are very similar to that shown in FIG. 6 which corresponds to the secretion of IL-5.
- No secretion is observed in the groups which received wild MVA (this is normal, it is a negative control).
- Low concentrations are obtained for the MVA Gag groups, 2 or 3 injections, and the groups combining DNA and PLA. Average concentrations are obtained for the groups of mice immunised by the compositions PLA and MVA. The strongest concentrations are obtained in the groups which received only PLA.
- the secretion of cytokines is therefore oriented more or less towards the type Th2 cytokines as a function of the vaccine composition:
- Th2 cytokines are not secreted at the same concentration.
- IL-4 and IL-10 are secreted at high levels.
- the following table recapitulates the mean concentrations of the different cytokines observed in the groups which have received the compositions PLA and MVA.
- the interleukin 4 is secreted by type CD4+ T lymphocytes. It increases the growth and the differentiation of the previously activated B lymphocytes, favours the production of IgE which plays an important part in the immediate hypersensitivity reactions. It also activates the macrophages.
- the interleukin 5, IL-5 stimulates the growth, the differentiation and the activation of eosinophils which play an important part in the fight against parasitic infections.
- the increase in the number of eosinophils is not only a sign of parasite attack but also a means of defence.
- the IL-5 induces the proliferation of B lymphocytes and their secretion of immunoglobulins. It activates cytotoxic T lymphocytes. Its use in the treatment of certain parasitic diseases can be envisaged.
- the interleukin 6, IL-6 stimulates the growth and the differentiation of B lymphocytes and increases the generation of platelets. By activation of the hepatocytes it causes the secretion of proteins of inflammation like fibrinogen and reactive protein C. It has a pro-inflammatory role, It has a cytotoxic effect with respect to certain tumours.
- FIG. 7 shows the secretion of the specific cytokine IL-2 of the protein p24. All the animals immunised during the 3 successive experiments were included in the analysis when the quantity of cells available permitted it. For each vaccine composition the number of animals which received this composition is indicated in brackets. The cells obtained from mice of one and the same group were pooled before being cultured for the secretion test. The Y axis shows the concentration of IL-2 (in pg/ml) secreted in the culture medium in response to a stimulation for 3 days by the protein p 24.
- IL-2 is a growth factor for T lymphocytes. It activates the transformation thereof into type CD8+ cytotoxic T lymphocytes which secrete interferon a, which stimulates macrophages to release TNF ⁇ and TGF ⁇ (transforming growth factor ⁇ ). IL-2 stimulates the growth and the cytolytic activity of NK (natural killer) cells. It stimulates the maturation of B lymphocytes and the synthesis of antibodies. This is a Th1 type cytokine.
- FIG. 8 shows an appearance kinetics of the specific humoral responses of the protein p24.
- compositions As a function of the type of response analysed, the best composition is not always the same, as certain compositions specifically obtain very good responses.
- composition PLA+MVA the composition PLA+MVA.
- the immunisation experiments were carried out in female BALB/c (H-2K d ) mice aged from 6 to 8 weeks at the time of the first immunisation.
- the Gag gene (SEQ ID No. 1) was cloned in the eukaryotic expression plasmid phCMV (non-commercial plasmid). DNA preparations without endotoxins and in large quantity have been produced with the Gigaprep endotoxin-free kit from Macherey-Nagel.
- the DNA serves as positive control, since it is known that in mice the administration of naked DNA by the intramuscular route makes it possible to induce a good cytotoxic response (CTL).
- CTL cytotoxic response
- mice received 2 doses of the immunogens described in point 2 above at 0 to 3 weeks.
- the vaccine compositions received by each group of mice are indicated in Table 6 below. All the injections were carried out by the intramuscular route for the adenovirus and the DNA and sub-cutaneously for the PLAs.
- the animals were sacrificed 3 weeks after the last injection and the blood and the spleen were removed for immunological analyses.
- Example 2 Carried out to the same procedures as in Example 1. Moreover, we have measured the humoral responses directed against the adenovirus5 using an ELISA technique. The procedure is identical to that used for the anti-p24 ELISA, except that an adenovirus lysate is used in capture.
- FIG. 9 shows the CTL responses obtained during the immunisation experiment No. 2.
- Each group consist of 5 mice, analysed individually. As the non-specific stimulation (without peptide) in all the groups is 0 it is not shown.
- the X axis corresponds to the ratio of effector cells (CTL) to target cells (to be lysed).
- mice out of 5 developed a CTL response, except for one mouse of the Ad5Gag 10 7 +PLA group.
- FIG. 10 shows the specific ELISPOT IFN- ⁇ responses of the Gag peptide AMQ.
- the Y axis shows the mean number of cells secreting the IFN- ⁇ in a specific manner in response to a stimulation for 18 hours by the Gag peptide AMQ on one million stimulated cells. This response was determined individually for each mouse (numbered from 1 to 5 for each mouse, thus Hi corresponds to the mouse 1 which had received the composition H Ad5 Gag 10 8 ip and Ad5 Gag 10 8 ip, etc. The number presented on this graph corresponds to a mean of triplicates.
- Example 1 we tested the secretion of 10 cytokines in the supernatant. Amongst these IL-5, IL-6, IL-17 and IFN- ⁇ were not secreted or were secreted at infinitesimal concentrations. As for GM-CSF, TNF- ⁇ and IL-1 ⁇ , their secretion was not specific for the protein p24 by the dosage technique used. It is very probable that it is the immunisation by the adenovirus which causes the secretion of these cytokines. If a specific secretion of the protein p24 exists, it is embedded in that caused by the adenovirus.
- FIG. 11 shows the secretion of the cytokines IL-2, IL-4 and IL-10 specific for the protein p24.
- Each vaccine composition was administered to 5 mice. The cells obtained from mice of one and the same group were pooled before being cultured for the secretion test.
- the Y axis shows the concentration of each cytokine (in pg/ml) secreted in the culture medium in response to stimulation for 3 days by the protein p24.
- composition Ad+Ad (H and H′) induces a rather polarised Th1 cytokine response (measured by ELISPOT IFN- ⁇ ).
- composition PLA+Ad 5 (J and J′) induces a non-polarised cytokine response, since not only Th1 cytokines such as IFN- ⁇ (by ELISPOT) and IL-2, but also Th2 cytokines such as IL-4 and IL-10 are detected.
- FIG. 12 shows the appearance kinetics of the humoral responses.
- FIG. 12(A) shows the antibody response directed against the protein p24 and
- FIG. 12(B) shows the antibody response directed against the adenovirus.
- Each vaccine composition was administered to 5 mice.
- the Y axis shows the titre of IgG measured by ELISA; the scale of this axis is logarithmic.
- S3 week 3
- S6 week 6.
- the anti-adenovirus response (or anti-vector response) is approximately 1 log less in the groups which received the compositions Ad+PLA (I and I′) and PLA+Ad (J and J′) than for Ad+Ad (H and H′).
- compositions according to the invention therefore make it possible to decrease the anti-adenovirus immunity.
- the immunisation experiments were carried out in female BALB/c (H-2K d ) mice aged from 6 to 8 weeks at the time of the first immunisation.
- mice received 2 doses of the immunogens described in point 2 above at 0 and 3 weeks.
- the vaccine compositions received by each group of mice are indicated in Table 7 below. All the injections were carried out subcutaneously except for the DNA which was administered by the intramuscular route.
- the animals were sacrificed 6 weeks after the first injection and the blood and the spleen were removed for immunological analyses.
- Example 2 Carried out according to the same procedures as in Example 1. Moreover, we have measured the humoral responses directed against the MVA using an ELISA technique. The procedure is identical to that used for the anti-p24 ELISA, except that a MVA lysate is used in capture.
- FIG. 13 shows the specific ELISPOT IFN- ⁇ responses of the Gag peptide AMQ.
- FIG. 14 shows the specific ELISPOT IL-4 responses of the protein p24.
- the best immunogen consists of the combination MVA Gag and PLA/p24 (B and C). Regardless of the order of administration of this composition, the IL-4 responses obtained are greater than those induced by the compositions MVA Gag+alum/p24 (regardless of the order) (K and L), PLA/p24+DNA Gag (G) and alum/p24+DNA Gag (M). If the order of administration of the products is now considered, it is always the composition PLA/p24+MVA Gag (C) which gives better results than the inverse combination MVA Gag+PLA/p24 (B).
- FIG. 15 shows an appearance kinetics of the specific humoral responses of the protein p24.
- the best immunogen again consists of the combination MVA Gag and PLA/p24 (B and C).
- the titres of anti-P4 IgG obtained are 0.6 to 1.2 log higher at week 6 than those induced by the compositions MVA Gag+alum/p24 (regardless of the order) (K and L), PLA/p24+DNA Gag (G) and alum/p24+DNA Gag (M).
- K and L the order of the order
- M alum/p24+DNA Gag
- M alum/p24+DNA Gag
- FIG. 16 shows the appearance kinetics of the specific humoral responses of the MVA virus.
- the Y axis shows the titre of anti-MVA IgG measured by ELISA for capture of MVA.
- the MVA was administered at week 3.
- the anti-MVA response did not have time to become established at the time of the analysis, at week 6.
- the anti-MVA response is much lower in the group MVA Gag+PLA/p24 (B) than in the group MVA Gag+alum/p24 (K).
- the anti-MVA titre does not increase in time, which is not the case with the combination MVA Gag+alum/p24.
- compositions according to the invention make it possible to induce better cell and humoral responses than the compositions alum/p24 and MVA Gag. Moreover, they make it possible to limit the anti-vector response.
- the immunisation experiments were carried out in female BALB/c (H-2K d ) mice aged from 6 to 8 weeks at the time of the first immunisation.
- mice received 3 doses of the immunogens described in point 2 above at 0, 10 and 20 days.
- the vaccine compositions received by each group of mice are indicated in Table 8 below. All the injections were carried out intranasally.
- the animals were sacrificed 32 days after the first injection.
- the blood, vaginal secretions, faeces, spleen and genital apparatus (vagina) were removed for immunological analyses.
- the ELISPOT measures the number of cells secreting cytokine per 10 E 6 cells analysed
- the intranasal administration of the combinations PLA/p24 and MVA Gag makes it possible to induce both a measured systemic immune response in the taking of blood and spleen, and a peripheral immune response at the mucous level, in particular at the level of the urogenital tract.
- the two arms of the immune system are activated: at the level of these two sites it has been possible to demonstrate cell and humoral immune responses directed against the protein p24.
- the capacity to induce a wide peripheral response at the level of the urogenital tract constitutes a considerable advantage for the combinations PLA/p24 and MVA Gag in the vaccine applications for prophylactic or therapeutic purposes.
- the immunisation experiments were carried out in female BALB/c (H-2K d ) mice aged from 6 to 8 weeks at the time of the first immunisation.
- mice received 2 doses of the immunogens described in point 2 above at 0 to 3 weeks.
- the vaccine compositions received by each group of mice are indicated in Table 10 below. All the injections were carried out subcutaneously.
- the animals were sacrificed 6 weeks after the first injection and the blood and the spleen were removed for immunological analyses.
- Humoral response blood was taken from the mice before they were sacrificed. The presence of anti-beta-gal antibodies was determined by ELISA. The protein beta-gal was used in capture and the specific antibodies present in the serum were revealed by a polyclonal anti-mouse antibody as detection antibody which is an Affinipure goat anti-mouse IgG antibody conjugated with horseradish peroxidase (H+ L, Jackson Immunoresearch, Cat no 115-035-062). The titre is the inverse of the dilution for which an absorbency of 0.1 OD unit is obtained with the ELISA protocol used.
- FIG. 17 shows the specific ELISPOT IFN- ⁇ responses of the beta-gal peptide TPH.
- FIG. 18 compares the appearance kinetics of the specific humoral responses of the protein beta-gal.
- the Y axis shows the titre of anti-beta-gal IgG measured by beta-gal capture ELISA; the scale of this axis is logarithmic.
- S3 week 2, S6 week 6.
- Example 1 changing an injection from PLA to MVA in a vaccination scheme does not to much harm to the titres of antibodies obtained but makes it possible to widen the cell responses with respect to those which are generated solely by a PLA vector.
- the immunisation experiments were carried out in female BALB/c (H-2K d ) mice aged from 6 to 8 weeks at the time of the first immunisation.
- mice received 2 doses of the immunogens described in point 2 above at 0 to 3 weeks.
- the vaccine combinations received by each group of mice are indicated in Table 11 below. All the injections were carried out subcutaneously.
- the animals were sacrificed 6 weeks after the first injection and the blood and the spleen were removed for immunological analyses.
- FIG. 19 shows the specific ELISPOT IFN- ⁇ responses of the p24 peptide AMQ.
- the combination CPL+MVA is effective for inducing a secretion of specific IFN- ⁇ of the peptide AMQ.
- the simultaneous injection of the two immunogens does not make it possible to improve performances with respect to administration separated by 3 weeks (Z vs V).
- FIG. 20 compares the appearance kinetics of the specific humoral responses of the protein p24.
- the Y axis shows the titre of anti-p24 IgG measured by ELISA for capture of p24; the scale of this axis is logarithmic.
- a colloidal synthetic bioresorbable vector such as PLA, CPL
- a viral vector such as MVA and adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Carbon And Carbon Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to pharmaceutical compositions containing a colloidal synthetic bioresorbable vector which comprises at least one type of proteinic substance, to a viral vector corresponding to at least one type of proteinic substance of the synthetic vector and to a method for the prophylactic, therapeutic and diagnosis use thereof.
Description
- The present invention relates to the field of prophylactic and therapeutic vaccination. In particular, the present invention relates to a vaccine composition comprising a viral vector enabling expression of protein substances and a synthetic vector having protein substances.
- Historically, the antigens used in the vaccines are either living microorganisms, the pathogenic power of which has been attenuated, or killed microorganisms. However, these vaccines often cause undesirable secondary effects during administration and in rare cases they cause very serious complications. Thus for a number of years in order to ensure vaccine safety priority is given to the use of purified fractions of microorganisms in vaccines. Such an immunogen, administered alone, can sometimes not induce a sufficient immune response. According to the prior art numerous vaccine strategies have been developed in order to increase or orient the immune response induced by the purified immunogens present in a vaccine.
- The most direct strategy is to combine the relevant protein substance (immunogen) with an adjuvant. Although numerous types of adjuvants are being developed, until recently aluminium hydroxides (alum) were the only adjuvant allowed for administration to humans. However, alum is a weak adjuvant for inducing humoral responses, it is not appropriate for all antigens and does not enable cell responses to be obtained. Amongst the adjuvant currently being developed, the most effective systems for inducing strong immunity are synthetic vectors based on microparticles and in particular microparticles of polylactic-co-glycolic acid (PLGA) and polylactic acid (PLA). Due to their size these particles make it possible to target antigen presenting cells such as macrophages or dendritic cells and improve the take-up of the immunogen by the immune system. The protein substance can be either encapsulated in the microparticles or adsorbed on the surface. The two approaches make it possible to induce both cellular and humoral immune responses, even if they were originally used above all in order to obtain an antibody response. However, encapsulation has two major drawbacks. The first is that a partial or total degradation of the microparticles is required for the protein substance to become available to the immune system, also the establishment of immunity is delayed. The second drawback is that the protein substance can be denatured or degraded during encapsulation and thus can lose its immunogenic properties. For these reasons this process cannot be used with every type of protein substance, whilst the process by adsorption does not have these drawbacks. In the two cases, the major obstacle to their use is their lack of effectiveness for generating specific cell responses. If by comparison with alum the cell responses induced are even better, they are well below what can be obtained with a viral vector.
- Recombinant viral vectors enable expression in vivo (in animals or in humans) of the relevant protein substance. This is an effective strategy which enables good mobilisation of the immune system. However, the induction of a lasting immune response necessitates the use of attenuated living vectors which can replicate in the vaccinated organism. For statutory reasons associated with the safe use of vaccines, new generations of vaccines use viral vectors which are non-replicative in humans, resulting in a diminution of the specific immune responses in time. Thus in the case of prophylactic vaccines it is still sometimes necessary to restimulate the specific immunity in order to maintain an effective memory response. In the field of immunotherapy, restimulation of the specific immunity remains useful for maintaining the intensity of the immune responses which enable control of the pathogenic organism. Thus the repeated administration of viral vectors appears necessary but is accompanied by a major problem which is the problem of anti-vector immunity. For the viral vector is itself an immunogen and as it is administered several times the specific immunity of the vector appears and then increases. This immune response is intended to eliminate the viral vector and also prevents the expression of the gene which it carries, thus resulting in a decrease in the effectiveness of the immune responses against the relevant protein substance. Moreover, the anti-vector immunity prevents the use of the vector in question for vaccination against another disease. Schagen et al describe certain approaches which make it possible to alleviate this anti-vector immunity, such as modifications at the level of the vector or even adaptations at the level of the vaccinated patients (2004, Critical Reviews in Oncology/Hematology 50:51-70). However, the implementation of these approaches is difficult and cannot be achieved for all diseases or all patients. Therefore the strategy which uses viral vectors is not optimised.
- Another way of improving the immune response induced by vaccination is the prime-boost strategy. It consists of increasing the specific immune responses by administering sequentially two different vaccines which carry one and the same protein substance instead of administering the same vaccine several times. For example, it is possible to use a different viral vector at each injection (Negri D R, et al, 2004, Journal of General Virology, 85: 1191-1201). However, this strategy only has a few chances of success because the number of viral vectors which are authorised for use in humans is very restricted. Moreover, the repeated administration of these viral vectors again encounters the problem of anti-vector immunity. In order to circumvent this problem, Otten et al describe the use of a DNA prime followed by a boost of PLGA microparticles with protein antigens adsorbed on the surface thereof (2003, Journal of Virology, 77: 6087-6092). Sharpe et al proposed a DNA prime encapsulating DNA in PLGA-based microparticles and a boost by a viral vector MVA (2003, Virology, 313: 13-21). O'Hagan et al describe the use of a prime by the DNA adsorbed on PLGA microparticles, followed by a boost by a vaccine vector (2001, Journal of Virology, 75: 9037-9043). Patent Application WO98/56919A describes a DNA prime followed by a boost by a poxvirus. The drawback of the use of a DNA prime is its low effectiveness particularly in primates and also when the gene is not very immunogenic such as for example the HIV-1 Tat gene. Patent Application WO98/56919A also describes the use of a prime by VLPs (virus-like particles), followed by a boost by a poxvirus. The VLPs are defective viral particles which do not incorporate the viral genome and which cannot reproduce. They are often formed by self-assembly of the structural proteins of a virus or of a retrotransposon (endogenous element similar to a retrovirus) such as the precursor Pr55 Gag of HIV-1 or the proteins L1 and L2 of HPV-16 (human papilloma virus). As a function of the viral proteins expressed the structure of the VLP may be close to or less than that of the native virion, such that the VPLs are comparable to a virus. The drawback of these VLPs is that that they are the result of biotechnology and that their manufacture according to the statutory standards is very difficult.
- The Applicants have now demonstrated, against all expectations, that the particular association of a colloidal synthetic bioresorbable vector comprising protein substances, and a viral vector comprising the nucleotide sequences which code for the corresponding protein substances, makes it possible to increase the effectiveness of the vaccination associated with the use of a protein substance, whilst decreasing the anti-vector immunity.
- Thus a first object of the invention consists of a pharmaceutical composition comprising or consisting of:
-
- a colloidal synthetic bioresorbable vector comprising at least one protein substance,
- a viral vector comprising at least one nucleotide sequence which codes for a protein substance corresponding to at least one protein substance of the synthetic vector,
- optionally in association with a pharmaceutically acceptable excipient.
- Another object of the invention consists of the use of the said composition for the preparation of a medicament, preferably a vaccine. It can also be used for the in vitro diagnosis of pathological states relating to the protein substances of the composition according to the invention.
- The present invention therefore proposes a novel composition comprising a colloidal synthetic bioresorbable vector having at least one protein substance.
- A bioresorbable compound is understood to be a compound which is not toxic, that is to say a compound of which the administration in the organism does not cause a lethal, disabling or inconvenient physiological or metabolic modification in day-to-day living, and which can be eliminated by natural means from the organism after administration.
- The terms colloid and colloidal define any dispersion of a substance (dispersed phase) within an aqueous continuous phase of which at least one of the three dimensions is less than or equal to 10 μm and preferably less than or equal to 1 μm.
- An aqueous continuous phase is a phase of which the composition is principally water, such 30 as for example a buffer or a water-miscible water/organic solvent mixture. Of course, an aqueous continuous phase appropriate to the purposes of the invention is a non-toxic phase.
- The disperse phase can be a liquid which is insoluble in the continuous phase such as for example an oil or a mixture of oils, or organic fatty materials, or it can even be a polymeric or mineral solid. The disperse phase is always bioresorbable.
- Examples of the disperse phase include olive oil, sunflower oil, groundnut oil, rapeseed oil, or mixtures thereof; triglycerides; synthetic polymers such as polymers of hydroxyacid such as for example lactic acid, glycolic acid, hydroxybutyric acid, or compounds resulting from caprolactone; polypeptides such as the compounds resulting from caprolactone polymerisation; natural polymers such as for example polysaccharides such as hyaluronic acid, chitosan, or dextran.
- Examples of such bioresorbable colloids are given in Benita A. and Levy M. Y., 1993, Journal of Pharmaceutical Sciences, 82(11): 1069-1079 (liquid/liquid emulsions), Trotta M., et al, 2003, International Journal of Pharmaceutics, 257: 152-160 (lipid solid/liquid emulsions), and Jiang W., et al, 2005, Biodegradable poly(lactic-co-glycolic) acid microparticles for injectable delivery of vaccine antigens Advanced Drug Delivery Reviews, 57: 391, 410.
- The form of the colloidal synthetic vector is given by the disperse phase which may or may not be spherical, which may be homogeneous or may be constituted by a stack of laminas.
- The synthetic vector according to the invention is preferably of spherical nature. Even more preferably the vector is composed of microspheres. The terms microsphere and microparticle are used indiscriminately in the following description. A microparticle or microsphere is understood to mean a particle of a size at most in the micron range to enable them to enter the antigen presenting cells. A size at most in the micron range is understood to be a dimension smaller than or equal to 999 μm. Microparticles preferably have a particle diameter smaller than or equal to 3 μm. Even more preferably the particles according to the invention have a submicron size, preferably with a diameter between 150 and 900 nm, more preferably between 250 and 700 nm. The size of the particles is easily determined by techniques known to the person skilled in the art such as, for example, by using scanning electron microscopy, quasi-elastic scattering of light or transmission electron microscopy.
- According to one embodiment of the invention the colloidal synthetic vectors are polymer-based vectors.
- By way of example of polymer-based synthetic vectors, mention may be made of vectors comprising microparticles based on polymers such as poly(α-hydroxy acids), polyhydroxybutyric acids, polycaprolactones, polyorthoesters and polyanhydrides. The synthetic vector preferably comprises at least one bioresorbable polymer chosen from amongst a poly(α-hydroxy acid) such as poly(D-lactic acid), poly(L-lactic acid) (both known as PLA), polyglycolic acid (known as PLG), or a mixture of poly(α-hydroxy acids) such as a mixture of poly(D- and L-lactic acids), a mixture of poly(L-lactic acid) and polyglycolic acid, a mixture of poly(D-lactic acid) and polyglycolic acid, or a mixture of poly(D- and L-lactic acids) and polyglycolic acid. When the polymer is a mixture of poly(α-hydroxy acids) the proportion of each constituent can be easily determined by the person skilled in the art. Thus for example it is possible to use a racemic mixture of poly(D- and L-lactic acids) or a PLA/PLG mixture at various percentages known to the person skilled in the art. The colloidal synthetic vector according to the invention is preferably prepared from at least one polymer chosen from amongst the poly(α-hydroxy acids). More preferably, the particles according to the invention are free of stabiliser and surfactant so that they are not toxic. A toxic microparticle is understood to be a microparticle including at least one compound capable of causing biological problems, such as disturbances of the metabolism, in the organism which has received the microparticle. Such non-toxic particles can be prepared according to the protocol described in Patent Application WO2005/027871.
- According to another embodiment, the colloidal synthetic vector is prepared from at least one natural polymer such as those referred to above
- The composition according to the invention is useful for stimulating both a cell-mediated response and a humoral response. It is useful both in prophylaxis and therapy and in diagnosis.
- Thus the protein substances which are useful for the purposes of the invention and are carried by the synthetic vector can be any protein substances against which an immune response is to be triggered.
- An immune response is understood to be a cell-mediated response, a humoral response or both.
- A cell-mediated response is understood to be a response mediated by the T-lymphocytes and/or other leucocytes. This response is reflected in the induction of a lytic activity by the cytotoxic T lymphocytes and/or by the production of cytokines by the CD8+ T lymphocytes or by the helper T cells.
- A humoral response is understood to be a response mediated by the antibody molecules secreted by the B lymphocytes.
- A protein substance is understood to be any protein substance playing the role of antigen after addition to the vectors which are appropriate for the purposes of the invention such as peptides, proteins, protein fragments, polyproteins and glycoproteins, it being understood that the protein fragments have retained the relevant structure.
- Antigens are molecules capable of being recognised by an antibody of which they have induced the synthesis by an immune response and containing at least one epitope.
- Examples of protein fragments comprise for peptides, polypeptides and epitopes.
- Epitopes are peptides comprising between 3 and 15 and generally between 5 and 15 amino acids, consisting of the minimum peptide fragment against which an immune response is triggered.
- The synthetic vector has multiple copies of the protein substances. “At least one protein substance” is understood to mean at least several protein substances of the same type. “A type of protein substance” is understood to mean a set of protein substances which trigger the same immune response by production of the same antibodies (i.e. having the same immunity).
- The synthetic vector may therefore comprise:
-
- either protein substances of the same type and therefore constituting antigens associated with the same disease. Thus for example the synthetic vector may comprise as protein substance the protein p24 in the form of native protein and/or mutated protein and/or protein fragment, it being understood that the mutated protein and the fragment have retained their immunity;
- or protein substances of different types and constituting antigens associated with the same disease. Thus for example the synthetic vector may comprise several proteins of the human immunodeficiency virus (HIV) such as the Gag protein, the muted Gag protein which does not have the same immunity, the Tat protein, the Rev protein, the Nef protein, the Env protein;
- or protein substances of different types and constituting antigens associated with different diseases. Thus for example the synthetic vector may comprise at least one type of protein of HIV, such as the p24, Tat, Rev proteins and at least one type of protein of the hepatitis C virus (HCV) such as the proteins NS2, NS3, NS4.
- According to one embodiment of the invention, the synthetic vector comprises protein substances of different types and constituting antigens associated with the same disease.
- The protein substances may be of several origins such as viral or bacterial origin or of a pathology of non-infectious origin (such as cancer or a metabolic disease).
- According to a particular embodiment of the invention, the protein substance is an antigen of viral origin.
- When the protein substance is of viral origin, the viruses used are all viruses for which substances capable of an immune response are known.
- By way of example, mention may be made without any limitation of herpes viruses, hepatitis viruses such as hepatitis B virus (HBV) or hepatitis C virus (HCV), papilloma viruses (HPV), human immunodeficiency viruses (HIV), such as HIV-1 and HIV-2, different strains of the human influenza and avian influenza viruses.
- The nucleic sequences of the viruses which are appropriate for the purposes of the invention, as well as the proteins coded by the said sequences are widely known to the person skilled in the art and are available for example in databases such as GenBank.
- Thus for example the HIV virus has genes which code for structural proteins of the virus.
- The Gag gene codes for the protein which forms the core of the virion, including the p24 antigen. The Pol gene codes for the enzymes responsible for the reverse transcription (reverse transcriptase), cleavage (protease) and integration (integrase). The Env gene codes for envelope glycoproteins. It contains other genes (Tat, Rev, Nef, Vif, Vpr and Vpu (HIV-1) or Vpx (HIV-2) which code for proteins involved in the regulation of the expression of the genes of the virus (regulating proteins). The HIV genome also comprises the 5′ and 3′ LTRs (long terminal repeats) which comprise regulating elements involved in the expression of the genes of the virus.
- According to one embodiment of the invention, the protein substance used in the method according to the invention is a protein of the HIV virus. As an example of an antigen of the HIV virus mention may be made of regulating proteins or the Gag protein or the Env glycoprotein, the preferred regulating proteins being the Tat, Rev or Nef protein.
- In the case of the HCV, the 5′ end of its genome corresponds to a non-translated region adjacent to the genes which code for the structural proteins, the core protein of the nucleocapsid, the two envelope glycoproteins, E1 and E2, and a small protein known as p7. The 5′ non-translated region and the core gene are relatively well preserved in the different genotypes. The envelope proteins E1 and E2 are coded by regions which are more variable from one isolate to another. The p7 protein is an extremely hydrophobic protein which would constitute an ion channel. The 3′ end of the HCV genome contains the genes which code for the non-structural proteins (NS2, NS3, NS4, NS5) and for a non-coding 3′ region having a well preserved domain (Major M E, Feinstone S M, Hepatology, June 1997, 25(6): 1527-1538).
- The non-structural protein NS3 of the HCV is a protein of 630 amino acids which comprises two distinct structural domains: an N-terminal domain of 81 amino acids, endowed with an active serine protease activity which intervenes in the maturation of the viral protein (domain called NS3 protease), and a C-terminal domain of 549 amino acids, comprising a helicase activity associated with an NTP ase activity which plays a part in the reproduction of the viral genome (domain called NS3 helicase). This protein NS3 is relatively well preserved amongst the different genotypes of the virus, such that this protein constitutes a “candidate vaccine” antigen of choice.
- According to another embodiment of the invention, the protein substance is an antigen associated with tumours.
- For certain tumours express antigens which are potentially recognised by the CD8+ T lymphocytes even if they do not have their origin in an intense immune response. These are tumour-associated antigens (TAA) or tumour markers (Houghton AN, 1994, J Exp Med 180:10). By improving the presentation of the TAAs to the immune system it is possible to render them more immunogenic, thus the TAAs can serve as a base for the development of anti-cancer vaccines in the form of a recombinant protein or a synthetic peptide.
- In order to test the new immunotherapy strategies which aim to increase the knowledge of TAAs, Wang et al have developed an experimental model in mice (1995, Journal of Immunology, 154: 4685-4692). The tumour line CT26.WT, genetic base BALB/c, was transfected by the lacZ gene of Escherichia coli which codes for the enzyme beta-galactosidase in order to create the line CT26.CL25. The two lines are lethal in mice and their growth kinetics are similar. Administered in mice, the line CT26.CL25 is the origin of the formation of tumours which can be slowed down or indeed inhibited in the presence of an immune response against beta-galactosidase which constitutes a model TAA.
- The protein substances appropriate for the purposes of the invention can be obtained by genetic engineering techniques which include the steps of:
-
- culture of a microorganism or eukaryotic cells transformed with the aid of a nucleotide sequence which codes for the relevant protein substance, and
- recovery of the said protein substance produced by the said microorganism or the said eukaryotic cells.
- These techniques are well known to the person skilled in the art. For further details in this connection, reference may be made to the following work: Recombinant DNA Technology I, Editors Ales Prokop, Raskesh K Bajpai: Annals of the New York Academy of Sciences, Volume 646, 1991.
- When the relevant protein substances are small in size, they can also be prepared by conventional peptide syntheses which are well known to the person skilled in the art.
- The protein substance is combined with the colloidal vectors according to techniques which are known to the person skilled in the art, such as inclusion or bonding on the surface. As an example of the inclusion of the protein substance in the colloidal synthetic vector, mention may be made of encapsulation (Tamber H. et al, 2005, Adv Drug Deliv Rev, 57(3); 357-76). As an example of bonding of the colloidal substance to the colloidal synthetic vector, mention may be made of adsorption, as described in Patent Application WO2005/027871, or covalent grafting involving the formation of a chemical bond between a reactive group of the colloidal vector and another of the protein substance in a manner described for example in “Protein immobilization Fundamentals and Applications R. F. Taylor Ed, Marcel Dekker Inc., New York, 1991.
- According to a particular embodiment, the protein substances are added to the synthetic vectors by bonding and more preferably by adsorption, such as for example by mixing the microparticles with the protein substances and incubating them whilst stirring, for example at ambient temperature or at 37° C.
- The composition according to the invention also comprises a viral vector.
- The viral vector comprises at least one nucleotide sequence which codes for a protein substance corresponding to at least one protein substance of the synthetic vector.
- “Protein substance of the viral vector corresponding to at least one protein substance of the synthetic vector” is understood to mean that the protein substance of the viral vector constitutes an antigen associated with the same disease as the protein substance of the synthetic vector, regardless of whether it is the same type or a different type, as indicated above. When the protein substances are of a different type they must have at least one epitope in common, such as for example the Gag and p24 proteins.
- Thus the genome of the viral vector is modified so as to insert one or several nucleotide sequences which code for one or several protein substances constituting antigens of the same disease or of different diseases. Amongst these protein substances at least one corresponds to a protein substance of the synthetic vector, these protein substances constituting antigens associated with the same disease.
- According to a preferred embodiment, the viral vector comprises a nucleotide sequence which codes for a protein of HIV.
- Apart from the nucleotide sequence or sequences coding for at least one protein substance constituting an antigen associated with the same disease as the protein substance of the synthetic vector, the viral vector also comprises the means necessary for the expression of the said protein substance.
- “Means necessary for the expression of a protein substance” are understood to mean any means which enable the protein substance to be obtained, such as in particular a promoter, a transcription terminator, an origin of replication and preferably a selection marker.
- The means necessary for the expression of a protein substance are operably linked to the nucleic acid sequence which codes for the said substance. “Operably linked” is understood to mean a juxtaposition of the said elements necessary for expression and of the gene which codes for the protein substance, which are in a relation which enables them to function in the expected manner. For example, additional bases may exist between the promoter and the relevant gene as long as their functional relation is maintained.
- The means necessary for the expression of the protein substance may be homologous means, that is to say means included in the genome of the vector which is used, or they may be heterologous. In this latter case the said means are cloned with the relevant protein to be expressed.
- Examples of heterologous promoters comprise (i) viral promoters such as the promoter SV40 (simian virus 40), the promoter of the thymidine kinase gene of the herpes simplex virus (TK-HSV-1), the LTR of the Rous sarcoma virus (RSV), the intermediate early promoter of the human cytomegalovirus (CMV) and the adenoviral major late promoter (MLP), as well as (ii) any cellular promoter which controls the transcription of the genes which code for proteins in higher eukaryotes, such as the promoter of the constitutive phosphoglycerate kinase (PGK) gene (Adra et al, 1987, Gene, 60: 65-74), the promoter of the specific genes of liver alpha1-antitrypsin and FIX and the specific promoter SM22 of soft muscle cells (Moessler et al, 1996, Development, 122: 2415-2425).
- The said sequences contained in the viral vector can be linked directly to one another under the control of one single promoter and/or one single expression regulating element, or they can be separated by each being dependent upon independent promoters and/or expression regulators which may be identical or different.
- By way of viral vectors which are suitable for the purposes of the invention, mention may be made for example of the viral vectors of the adenovirus, poxvirus, baculovirus, herpes virus, togavirus, retrovirus type.
- Adenoviruses have been detected in numerous animal species. They do not integrate and are not very pathogenic. They are capable of infecting a variety of cell types, dividing cells and resting cells. They have a natural tropism for bronchial epitheliums. Moreover, they have been used as live enteric vaccines for a number of years with an excellent safety record. Finally, they can be easily grown and purified in large quantities. Due to these characteristics adenoviruses are particularly appropriate for use as expression vectors and in particular as gene therapy vectors for the purposes of therapy and vaccination.
- According to a preferred embodiment, the vector according to the invention is an adenovirus.
- Examples of adenoviruses to be used in the present invention may be derived from any source of human or animal origin, in particular of canine origin (for example CAV-1 or CAV-2; GenBank reference CAVIGENOM and CAV77082 respectively), of avian origin (GenBank reference AAVEDSDNA), of bovine origin (such as BAV3, Seshidhar Reddy et al, 1998, J. Virol., 72:1394-1402), of ovine, feline or porcine origin, of simian origin, or one of their hybrids. Any serotype may be used. However, the adenoviruses of human origin are preferred and in particular the adenovirus 5 (Ad5).
- In general, the viruses referred to are available in the ATCC collections and have been the subject of numerous publications describing their sequences, their organisation and their biology, which enables the person skilled in the art to apply them easily. For example, the sequence of the
adenovirus type 5 is described in the GenBank database (M73260 and M29978) and is incorporated herein by reference. - The genome of adenoviruses consists of a linear double-strand DNA molecule of approximately 36 kb carrying more than approximately 30 genes necessary for terminating the viral cycle. There are 4 early genes distributed in the genome of the adenovirus (E1 to E4). The regions E1, E2 and E4 are essential for the viral replication. The region E3 is considered as a non-essential region based on the observation that mutant viruses appear naturally or hybrid viruses which have lost this region E3 continue to replicate like viruses of the wild type in cultured cells (Kelly and Lewis, 1973, J. Virol., 12: 643-652). The majority of late genes (L1 to L5) code for the structural proteins which form the viral capsid. They at least partially overlap the first transcription motifs and are transcribed on the basis of single promoter (MLP for “major late promoter”). Moreover, the adenoviral genome carries at the two ends cis-action regions which are essential for the DNA replication respectively the
inverted repeat motifs 5′ and 3′ (ITRs for “inverted terminal repeats”) and a packaging sequence. - The adenoviruses currently used in the gene therapy protocols are devoid of the majority of region E1, which makes the viruses deficient at the replication level in order to prevent their dissemination in the environment and in the host organism. Moreover, the majority of adenoviruses are also devoid of region E3 in order to increase their cloning capacity. The feasibility of gene transfer using these vectors has been demonstrated in a variety of tissues in vivo (see for example Yei et al, 1994, Hum. Gen. Ther., 5: 731-744; Dai et al, 1995, Proc. Natl. Acad. Sci. USA, 92: 1401-1405; U.S. Pat. No. 6,099,831; and U.S. Pat. No. 6,013,638).
- Another expression vector which is particularly appropriate for the purposes of the invention is a poxvirus, which constitutes another embodiment of the invention.
- Poxviruses constitute a group of complex enveloped viruses which are distinguished principally by their unusual morphology, their large DNA genome and their cytoplasmic replication site. The genome of several elements of the poxyiridiae, comprising the viral strain of the Copenhagen vaccinia (VV) (Goebel et al, 1990, Virol. 179: 247-266 and 517-563) and the strain of the Modified Vaccinia Virus Ankara (MVA) (Antoine et al, 1998, Virol., 244: 635-396), has been mapped and sequenced. The strain VV has a double-strand DNA genome of approximately 192 kb which codes for approximately 200 proteins of which approximately 100 are involved in the assembly of the virus. The strain MVA is a highly attenuated strain of the vaccinia virus, generated by more than 500 serial passages of the Ankara strain of the vaccinia virus (CVA) on chicken embryo fibroblasts (Mayr et al, 1975, Infection, 3: 6-16). The virus MVA has been deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) under the number 1-721. The determination of the complete sequence of the genome of MVA and the comparison with that of VV enables precise identification of the alterations which have occurred in the viral genome and the definition of seven deletions (I to VII) and numerous mutations leading to fragmented open reading frames (Antoine et al, 1998, Virology, 244: 365-396).
- Other examples of poxviruses which are appropriate for the purposes of the invention comprise canarypox, fowlpox, cowpox, entomopox, monkeypox, swinepox and penguinpox.
- Poxvirus occurs in two morphologically distinct forms, known as intracellular mature virus (IMV) and extracellular enveloped virus (EEV).
- The poxvirus used for the purposes of the invention is preferably a modified vaccinia virus Ankara.
- The methods of suppression and insertion of DNA sequences in expression vectors are widely known by the person skilled in the art and consist in particular of steps of enzymatic digestion and ligation. The nucleotide sequence inserted into the viral vector preferably codes for a protein of the HIV virus.
- The compositions based on vectors according to the invention are particularly effective for inhibiting, preventing and treating a disease for which the protein substance of the composition constitutes an antigen, such as an infection by a virus. They are therefore particularly useful for the preparation of a medicament, in particular a vaccine, which may be therapeutic or prophylactic.
- Thus the invention also relates to a method of prophylactic or therapeutic treatment, in particular vaccination, comprising the administration to a patient of an effective dose of the composition according to the invention.
- The pharmaceutical compositions according to the invention are appropriate for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal, rectal, vaginal, intraocular, intraauricular administration, and the said active principle can be administered in unitary administration form.
- The unitary administration forms may be for example tablets, capsules, granules, powders, injectable oral solutions or suspensions, transdermal patches, sublingual, buccal, intratracheal, intraocular, intranasal, intraauricular forms of administration, forms of administration by inhalation, topical forms of administration such as rectal or vaginal, transdermal, subcutaneous, intramuscular or intravenous forms of administration, or implants. For topical administration creams, gels, ointments, lotions or collyria may be envisaged.
- These Galenic forms are prepared by the usual methods in the fields in question.
- The said unitary forms are dosed in order to enable daily administration of 0.001 to 10 mg of active principle per kg of body weight depending upon the Galenic form.
- There may be particular cases where higher or lower dosages are appropriate; such dosages do not depart from the scope of the invention. According to usual practice, the appropriate dosage for each patient is determined by the doctor according to the mode of administration, the weight and the response of the patient.
- The quantity and the nature of the excipient can be easily determined by the person skilled in the art. They are chosen as a function of the pharmaceutical form and the mode of administration which are required.
- The composition according to the invention can be contained in a pharmaceutical kit. The administration of the composition according to the invention may be simultaneous, separate or staggered.
- Simultaneous administration is understood to mean administration of the composition at the same time and at the same location.
- Staggered administration is understood to mean the administration of the viral vector or the synthetic vector at different times. The interval between each administration may extend from a few minutes to several years, preferably from several weeks to several months and more preferably it may be 3 or 4 weeks.
- Separate administration is understood to mean the administration of the viral vector and the synthetic vector at different locations on the body. The viral vector and the synthetic vector may be in the same excipient or preferably in appropriate different excipients.
- The composition according to the invention is preferably administered in a staggered manner. More preferably the synthetic vector is administered before the viral vector.
- Thus according to an embodiment of the invention, the composition according to the invention comprises:
- i) a prime constituent consisting of the colloidal synthetic bioresorbable vector comprising at least one protein substance and
- ii) a boost constituent consisting of the viral vector comprising at least one nucleotide sequence which codes for a protein substance corresponding to at least one protein substance of the synthetic vector.
- In addition to a therapeutic and prophylactic application, the invention also has a diagnostic application. Thus the invention also relates to the use of the composition according to the invention for the diagnosis in vitro of the pathological state for which the protein substance or substances of the synthetic vector and of the synthetic vector constitute antigens, and in particular of a viral infection or a cancer.
- The present invention will be better understood with the aid of the following examples which are given solely by way of illustration and are not limiting, and also with the aid of the appended
FIGS. 1 to 20 , in which: -
FIG. 1 shows the CTL responses during the immunisation experiment No. 1 with different vaccine compositions including the compositions according to the invention which comprise a synthetic vector based on microparticles of poly(D,L-lactic acid) combined with protein p24 (referred to hereafter as PLA/p24) and a viral vector MVA comprising the Gag sequence (referred to hereafter as MVA Gag virus). -
FIG. 2 shows the specific ELISPOT IFN-γ responses of the Gag AMQ peptide during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag. -
FIG. 3 shows the specific ELISPOT IFN-γ responses of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag. -
FIG. 4 shows the specific ELISPOT IL-4 responses of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag. -
FIG. 5 shows the secretion of the specific cytokine GM-CSF of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag. -
FIG. 6 shows the secretion of the specific cytokine IL-5 of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag. -
FIG. 7 shows the secretion of the specific cytokine IL-2 of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag. -
FIG. 8 shows the appearance kinetics of the specific humoral responses of the protein p24 during the 3 immunisation experiments with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector MVA Gag. -
FIG. 9 shows the CTL responses during the immunisation experiment No. 2 with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector Adenovirus Gag. -
FIG. 10 shows the specific ELISPOT IFN-γ responses of the Gag AMQ peptide after immunisation with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector Adenovirus Gag. -
FIG. 11 shows the specific secretion of the protein p24 of the cytokines IL-2, IL-4, IL-10 after immunisation with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector Adenovirus Gag. -
FIG. 12 shows the appearance kinetics of the specific humoral responses of the protein p24 (12A) or of the adenovirus (12B) after immunisation with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA/p24 and the viral vector Adenovirus Gag. -
FIG. 13 compares the specific ELISPOT IFN-γ responses of the peptide Gag AMQ after immunisation with different vaccine compositions including the compositions which comprise PLA/p24 and MVA Gag or comprise alum/p24 and MVA Gag. -
FIG. 14 compares the specific ELISPOT IL-4 responses of the protein p24 after immunisation with different vaccine compositions including the compositions which comprise PLA/p24 and MVA Gag or comprise alum/p24 and MVA Gag. -
FIG. 15 compares the appearance kinetics of the specific humoral responses of the protein p24 after immunisation with different vaccine compositions including the compositions which comprise PLA/p24 and MVA Gag or comprise alum/p24 and MVA Gag. -
FIG. 16 compares the appearance kinetics of the specific humoral responses of the MVA virus after immunisation with different vaccine compositions including the compositions which comprise PLA/p24 and MVA Gag or comprise alum/p24 and MVA Gag. -
FIG. 17 shows the specific ELISPOT IFN-γ responses of the peptide beta-gal TPH after immunisation of mice with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA-beta-gal and the viral vector MVA beta-gal. -
FIG. 18 compares the appearance kinetics of the specific humoral responses of the beta-gal after immunisation of mice with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector PLA-beta-gal and the viral vector MVA beta-gal. -
FIG. 19 shows the specific ELISPOT IFN-γ responses of the peptide p24 AMQ after immunisation of mice with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector CPL-P24 and the viral vector MVA Gag. -
FIG. 20 compares the appearance kinetics of the specific humoral responses of the peptide p24 AMQ after immunisation of mice with different vaccine compositions including the compositions according to the invention which comprise the synthetic vector CPL-P24 and the viral vector MVA Gag. - The vaccine composition used comprises a synthetic vector based on microparticles of poly(D,L-lactic acid) combined with protein p24 (referred to hereafter as PLA/p24) and a viral vector MVA comprising the Gag sequence of SEQ ID No 1 (referred to hereafter as MVA Gag virus).
- The immunisation experiments were carried out in female BALB/c (H-2Kd) mice aged from 6 to 8 weeks at the time of the first immunisation.
- In this series of experiments the following immunogens were used alone or in combination:
-
- microparticles PLA/p24 prepared according the solvent displacement and adsorption procedure of Patent Application WO2005/027871.
- the virus MVA Gag (modified vaccinia virus Ankara, attenuated vaccinia virus, Ankara strain) which is recombinant for the Gag gene of the HIV-1 virus, coding for the protein p24. The recombinant virus was constructed at Transgene from the wild strain (MVATGN33) as described in Antoine G. et al, 1998, “The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses”, Virology, 244: 365-396. This recombinant virus was then produced and purified as follows: the MVA is replicated on chicken embryo cells. After 48 to 72 hours of infection the cells are harvested, then lysed by freezing/thawing and by sonication. The lysate is purified/concentrated by 2 saccharose pads optionally followed by 2 saccharose gradients.
- For more precise details reference may be made to the book “Current Protocols in Molecular Biology”,
Volume 2, Chapter 16.16, editors Ausubel F M, Brent R, Kigston R E, Moore D D, Seidman J G, Smith J A, Struhl K, John Wiley & Sons, Inc., New York. 3 volumes. -
- the wild MVA virus MVATGN33. This is a negative control which serves to measure whether the viral vector induces a non-specific immune response during the immunisations.
- Gag DNA. The Gag gene (from SEQ ID No. 1) was cloned in the eukaryotic expression plasmid phCMV (contains the intermediate/early promoter of the human cytomegalovirus and splicing and polyadenylation signals from the rabbit beta-globin gene (Y K Yee et al, 1994, Proc Natl Acad Sci USA, 91(20):9564-9568)). DNA preparations without endotoxins and in a large quantity have been produced using the Gigaprep endotoxin-free kit from Macherey-Nagel. The DNA serves as positive control, since it is known that in mice the intramuscular administration of naked DNA makes it possible to induce a good cytotoxic response (CTL).
- 35 mice received 2 doses of the immunogens described in
point 2 above at 0 and 3 weeks. The vaccine compositions received by each group of mice are indicated in Table 1 below. All the injections were carried out subcutaneously except for the DNA which was administered by the intramuscular route. -
TABLE 1 Dose Dose 1st injection 2nd injection Week 0 Week 3Number of mice MVA Gag 107 pfu MVA Gag 107 pfu 5 MVA Gag 107 pfuPLA/ p24 40μg 5 PLA/ p24 40μg MVA Gag 107 pfu 5 PLA/ p24 40 μgPLA/ p24 40μg 5 wild MVA 107 pfuwild MVA 107pfu 5 DNA Gag 10 μg (IM)PLA/ p24 40μg 5 PLA/ p24 40μg DNA Gag 10 μg (IM) 5 pfu = plaque forming units, this is the unit of measurement of the dose of MVA used. The viral titre is expressed in pfu according to the technique of dosage of the viral stock used, as indicated in Current Protocols in Molecular Biology, see above. - The animals were sacrificed 6 weeks after the first injection and the blood and the spleen were removed for immunological analyses.
- In this experiment the number of injections was increased.
- 30 mice received 2 or 3 doses of the immunogens described in
point 2 above at 0, 3 and 6 weeks. The vaccine compositions received by each group of mice are indicated in Table 2 below. All the injections were carried out subcutaneously. -
TABLE 2 1st injection 2nd injection 3rd injection Number Week 0 Week 3Week 6of mice MVA Gag 107 pfu MVA Gag 107 pfu 5 MVA Gag 107pfu MVA Gag 107 pfu MVA Gag 107 pfu 5 MVA Gag 107 pfuPLA/ p24 40μg 5 MVA Gag 107 pfuPLA/ p24 40 μgPLA/ p24 40μg 5 PLA/ p24 40μg MVA Gag 107 pfu 5 wild MVA 107 pfuwild MVA 107 pfuwild MVA 107pfu 5 - The animals were sacrificed 3 weeks after the last injection and the blood and the spleen were removed for immunological analyses.
- 30 mice received 2 or 3 doses of the immunogens described in
point 2 above at 0, 3 and 6 weeks. The vaccine compositions received by each group of mice are indicated in Table 3 below. All the injections were carried out subcutaneously. -
TABLE 3 1st injection 2nd injection 3rd injection Number of Week 0Week 3Week 6mice MVA Gag 107 pfu PLA/ p24 40μg 5 MVA Gag 107 pfuPLA/ p24 40 μgPLA/ p24 40μg 5 PLA/ p24 40μg MVA Gag 107 pfu 5 PLA/ p24 40μg MVA Gag 107 pfu PLA/ p24 40μg 5 PLA/ p24 40 μgPLA/ p24 40μg 5 PLA/ p24 40 μgPLA/ p24 40 μgPLA/ p24 40μg 5 - The animals were sacrificed 3 weeks after the last injection and the blood and the spleen were removed for immunological analyses.
- The humoral response and the cell response were researched as follows:
-
- Humoral response: blood was taken from the mice before they were sacrificed. The presence of anti-p24 antibodies was determined by ELISA. The protein p24 (produced with Escherichia coli and purified by metal chelate affinity chromatography according to Cheynet V. et al, 1993, Protein Expr Purif, 4(5): 367-72) was used in capture and the specific antibodies present in the serum were revealed by a polyclonal anti-mouse antibody as detection antibody which is an Affinipure goat anti-mouse IgG antibody conjugated with horseradish peroxidase (H+ L, Jackson Immunoresearch, Cat no 115-035-062). The titre is the inverse of the dilution for which an absorbency of 0.1 OD unit is obtained with the ELISA protocol used.
- Cell response: after sacrifice of the mice, the spleens were removed in a sterile manner in order to prepare a cell suspension. The following analyses were carried out on the cell suspensions obtained, each mouse having been analysed individually or in a pool when the quantity of cells was not sufficient for individual analysis.
(i) CTL test: The cell suspension was cultured in the presence of a peptide of the protein p24 of 9-mer (AMQMLKETI—SEQ ID No. 2) which corresponds to an immunodominant H-2Kd-restricted CTL epitope, and IL-2. Five days later, the effector population was restimulated by irradiated naive cells charged with the peptide. The cytotoxic effector population was harvested at the end of the 7th day and the CTL activity was measured using the cells P815 (ATCC TIB-64) marked with 51Cr as targets.
(ii) ELISPOT: ELISPOT makes it possible to determine the number of cells secreting a given cytokine in response to a specific stimulus. We are interested in the cytokines IFN-γ of type Th1 and IL-4 of type Th2. The cell suspensions obtained from the spleens were restimulated in vitro by the peptide AMQMLKETI for 20 hours in order to analyse the responses of type CD8. The cell suspensions obtained from the spleens were restimulated in vitro by the protein p24 (without endotoxins) for 42 hours in order to analyse the responses of type CD4.
- The 96-well ELISPOT plates with PVDF membranes (Multiscreen IP, Millipore) were coated by an anti-IFN-? or anti-IL-4 antibody. During the restimulation the suspensions of splenocytes were incubated in these plates in such a way as to capture the cytokines secreted by each cell. The spots corresponding to each cell secreting the relevant cytokine were revealed by a specific biotinylated detection antibody of the relevant cytokine.
- iii) Secretion of cytokines: The splenocytes were stimulated for 3 days in complete culture medium (culture medium: alpha minimal essential medium (αMEM) containing 10% foetal calf serum, 10 mM HEPES, 5×10−5 M ε-mercaptoethanol, 4 nM L-glutamine, 80 U/ml penicillin, 80 mg/ml streptomycin, non-essential amino acids 1x (cat. no. 11140-035), sodium pyruvate 1x (cat no. 11360-039) (constituents of Invitrogen, Cergy Pointoise, France)) in the presence or absence of the relevant p24 antigen, then the cytokines secreted in the culture supernatant were dosed by the mouse kit FlowCytomix Th1/Th2 10plex from Bender Medsystems (cat no. BMS720FF).
- Table 4 below recapitulates the results obtained during the 3 successive experiments:
-
TABLE 4 Frequency of mice with CTL response Number of positive Mice analysed mice/number of in pool mice analysed Code Vaccine composition ( Exp 1, n = 5)individually A MVA Gag + MVA Gag Negative 0/5 pool A′ MVA Gag + MVA Gag + 1/5 MVA Gag B MVA Gag + PLA/ p24 Negative 1/10 pool B′ MVA Gag + PLA/p24 + 3/10 PLA/p24 C PLA/p24 + MVA Gag Positive 2/10 pool C′ PLA/p24 + MVA Gag + 1/5 PLA/p24 F DNA Gag + PLA/p24 Positive Not carried out pool G PLA/p24 + DNA Gag Positive Not carried out pool D PLA/p24 + PLA/ p24 Negative 0/5 pool D′ PLA/p24 + PLA/p24 + 0/5 PLA/p24 E MVA + wild MVA Negative Not carried out pool E′ MVA + MVA + wild MVA 0/5 -
FIG. 1 shows the CTL responses obtained during the immunisation experiment No. 1. Each group consists of 5 mice, the spleens were pooled before the CTL dosage was carried out. Since the non-specific stimulation (without peptide) in all the groups was 0, this is not shown. Likewise, since the CTL responses obtained with the compositions A, D and E were 0, they are not shown. The X axis corresponds to the ratio of effector cells (CTL) to target cells (to be lysed). The Y axis corresponds to the mean lysis percentage. - The CTL responses induced are of low intensity with all the immunogens used (MVA, PLA or combinations), with the exception of the group G of Experiment I which received DNA last (
FIG. 1 ). The induction of CTL in the DNA groups is normal: the DNA is optimised for this purpose, it is a positive control in mice but does not work so well in primates. - Even if the responses remain low, the groups containing both MVA and PLA give better CTL responses than the groups which received MVA alone or PLA alone.
- When 2 injections were given, in the groups which received MVA twice or PLA twice there is no CTL detected during the retained sacrifice (A and D), whilst in the groups which received both PLA and MVA (B and C) there is a low frequency of CTL. The order of injection also plays a part: PLA+MVA (C) gives better results than MVA+PLA (B).
- When 3 injections were given, the frequency of induction of the responses still remains low. The CTL responses are not improved by comparison with two injections. The vaccine strategy using MVA necessitates 3 injections in order to give the same results as the combinations of PLA and MVA.
-
FIG. 2 shows the specific ELISPOT IFN-γ responses of the Gag peptide AMQ. All the animals immunised during the 3 successive experiments were included in the analysis. For each vaccine composition the number of animals which received this composition is indicated in brackets. The Y axis shows the mean number of cells secreting IFN-γ in a specific manner in response to a stimulation for 18 hours by the Gag peptide AMQ on a million stimulated cells. This response was determined individually for each mouse. The number presented on this graph corresponds to the calculated mean from all the mice of a group (n=5, 10 or 15 depending upon the groups). - The gamma or type II interferon is also called immune interferon because it is secreted by the type CD4+ T lymphocytes, by the type CD8+ T lymphocytes and the NK cells. It protects the cells against viral infections. It stimulates the phagocytic activity of macrophages, enabling them to kill the tumour cells. It stimulates the maturation of the T and B lymphocytes and increases the production of antibodies. It increases the expression of class I and II HLA molecules by the macrophages. It is a type Th1 cytokine.
- It is possible to classify the vaccine compositions into several categories as a function of the ELISPOT IFN-γ responses obtained. The best responses are induced by the compositions PLA+MVA (C) and MVA+MVA (A). In these cases the third injection either does not provide any improvement (composition MVA+MVA) (A′) or it can decrease the response observed (composition PLA+MVA) (C′). The compositions MVA+PLA (B and B′) and DNA+PLA (F) enable intermediate intensity responses to be generated, whilst the strategy using only PLA (D and D′) only induces low responses
- Thus we have been able to show that the vaccine composition PLA+MVA (C) was at least as good as, if not better than the combination MVA+MVA (A) for inducing a secretion of specific IFN-γ of the peptide AMQ.
-
FIG. 3 shows the specific ELISPOT IFN-γ responses of the protein p24. All the animals immunised during the 3 successive experiments were included in the analysis. For each vaccine composition the number of animals which received this composition is indicated in brackets. The Y axis shows the mean number of cells secreting IFN-γ in a specific manner in response to a stimulation for 42 hours by the protein p24 on a million stimulated cells. This response was determined individually for each mouse. The number presented on this graph corresponds to the calculated mean from all the mice of a group (n=5, 10 or 15 depending upon the groups). - Again it is possible to classify the vaccine compositions into several categories as a function of the ELISPOT IFN-γ responses obtained. The best responses are induced by the compositions PLA+MVA (C and C′) and DNA+PLA (F). The third injection further decreases the response observed in the case of the composition PLA+MVA (C′). The compositions MVA+PLA (B and B′) and MVA+MVA (A and A′) enable intermediate intensity responses to be generated, whilst the strategy using only PLA (D and D′) only induces low responses
- Thus we have been able to show that the vaccine composition PLA+MVA was the best choice for inducing a secretion of specific IFN-γ of the protein p24.
-
FIG. 4 shows the specific ELISPOT IL-4 responses of the protein p24. All the animals immunised during the 3 successive experiments were included in the analysis. For each vaccine composition the number of animals which received this composition is indicated in brackets. The Y axis shows the mean number of cells secreting IL-4 in a specific manner in response to a stimulation for 42 hours by the protein p24 on a million stimulated cells. This response was determined individually for each mouse. The number presented on this graph corresponds to the calculated mean from all the mice of a group (n=5, 10 or 15 depending upon the groups). - Once again it is possible to classify the vaccine compositions into several categories as a function of the ELISPOT IL-4 responses obtained. The best response is induced by the composition PLA+MVA (C and C′). Once again the third injection does not seem necessary since it only slightly improves the response induced by the composition PLA+MVA (C′). The compositions MVA+PLA (B and B′) and DNA+PLA (F) and PLA+PLA (D and D′) enable intermediate intensity responses to be generated, whilst the strategy using only MVA only induces low responses (A and A′).
- Thus we have been able to show that the vaccine composition PLA+MVA was the best choice for inducing a secretion of specific IL-4 of the protein p24.
- The study of the secretion of cytokines makes it possible to create a table of the state of immune activation of the animal which received the vaccine composition. The cytokines can be divided into four groups as a function of their properties:
- 1) The mediators of natural immunity (IFN-γ, IL-1, IL-6, IL-8 . . . )
- 2) The activators of the lymphocyte activation, growth and differentiation (IL-2, IL-4, IL-5, IL-6, IL-10, TGF-β)
- 3) The non-specific activators of inflammation (IFN-γ, IL-5, IL-8)
- 4) Activators and differentiators of immature leucocytes (IL-3, GM-CSF)
- By the use of a multiplex kit we have been able to dose the secretion of 10 different cytokines in the culture supernatants of the splenocytes obtained from the sacrificed animals. These cytokines are: IFN-γ, TNF-α, GM-CSF, IL-4, IL-17, IL-1α, IL-2, IL-5, IL-6, IL-10.
- None of the vaccine compositions tested induces a significant secretion of the cytokines IL-1α and IL-17.
- For all the other cytokines tested we have been able to demonstrate the differences between the groups.
-
FIG. 5 shows the secretion of the specific cytokine GM-CSF of the protein p24. All the animals immunised during the 3 successive experiments were included in the analysis when the quantity of cells available permitted it. For each vaccine composition the number of animals which received this composition is indicated in brackets. The cells obtained from mice of one and the same group were pooled before being cultured for the secretion test. The Y axis shows the concentration of GM-CSF (in pg/ml) secreted in the culture medium in response to a stimulation for 3 days by the protein p24. - The cytokine GM-CSF (granulocyte-macrophage colony stimulating factor) is a powerful immunostimulator which enables activation of the immune functions such as adhesion, phagocytosis, etc. of macrophages, neutrophiles and eosinophiles. As we can see in
FIG. 5 , we have shown a substantial secretion of GN-CSF in the groups containing PLA in association or not with MVA (except for when the number of injections is increased to 3 for the PLAs) whilst the groups immunised exclusively with MVA secretes little or none of it. -
FIG. 6 shows the secretion of the cytokine IL-5 specific of the protein p24. All the animals immunised during the 3 successive experiments were included in the analysis when the quantity of cells available permitted it. For each vaccine composition the number of animals which received this composition is indicated in brackets. The cells obtained from mice of one and the same group were pooled before being cultured for the secretion test. The Y axis shows the concentration of IL-5 (in pg/ml) secreted in the culture medium in response to a stimulation for 3 days by the protein p 24. - For all the type Th2 cytokines tested such as IL-4, IL-5, IL-6 and IL-10 the secretion profiles are very similar to that shown in
FIG. 6 which corresponds to the secretion of IL-5. No secretion is observed in the groups which received wild MVA (this is normal, it is a negative control). Low concentrations are obtained for the MVA Gag groups, 2 or 3 injections, and the groups combining DNA and PLA. Average concentrations are obtained for the groups of mice immunised by the compositions PLA and MVA. The strongest concentrations are obtained in the groups which received only PLA. The secretion of cytokines is therefore oriented more or less towards the type Th2 cytokines as a function of the vaccine composition: -
- a response mainly of type Th2 is observed for the groups immunised only with PLAs (the secretion of IFN-γ of IL-2, type Th1 cytokines is low (FIG. 7)),
- a non-polarised response both Th1 and Th2 for the groups immunised with the combinations PLA and MVA,
- for the MVA groups the secretion of type Th2 cytokines is low.
- We also note that the 4 dosed Th2 cytokines are not secreted at the same concentration. IL-4 and IL-10 are secreted at high levels. The following table recapitulates the mean concentrations of the different cytokines observed in the groups which have received the compositions PLA and MVA.
-
TABLE 5 Cytokine IL-4 IL-5 IL-6 IL-10 Mean conc. 2600 1460 260 2660 (pg/ml) - The
interleukin 4, IL-4, is secreted by type CD4+ T lymphocytes. It increases the growth and the differentiation of the previously activated B lymphocytes, favours the production of IgE which plays an important part in the immediate hypersensitivity reactions. It also activates the macrophages. - The
interleukin 5, IL-5, stimulates the growth, the differentiation and the activation of eosinophils which play an important part in the fight against parasitic infections. The increase in the number of eosinophils is not only a sign of parasite attack but also a means of defence. The IL-5 induces the proliferation of B lymphocytes and their secretion of immunoglobulins. It activates cytotoxic T lymphocytes. Its use in the treatment of certain parasitic diseases can be envisaged. - The
interleukin 6, IL-6, stimulates the growth and the differentiation of B lymphocytes and increases the generation of platelets. By activation of the hepatocytes it causes the secretion of proteins of inflammation like fibrinogen and reactive protein C. It has a pro-inflammatory role, It has a cytotoxic effect with respect to certain tumours. -
FIG. 7 shows the secretion of the specific cytokine IL-2 of the protein p24. All the animals immunised during the 3 successive experiments were included in the analysis when the quantity of cells available permitted it. For each vaccine composition the number of animals which received this composition is indicated in brackets. The cells obtained from mice of one and the same group were pooled before being cultured for the secretion test. The Y axis shows the concentration of IL-2 (in pg/ml) secreted in the culture medium in response to a stimulation for 3 days by the protein p 24. - IL-2 is a growth factor for T lymphocytes. It activates the transformation thereof into type CD8+ cytotoxic T lymphocytes which secrete interferon a, which stimulates macrophages to release TNFα and TGFα (transforming growth factor α). IL-2 stimulates the growth and the cytolytic activity of NK (natural killer) cells. It stimulates the maturation of B lymphocytes and the synthesis of antibodies. This is a Th1 type cytokine.
- It is possible to classify the vaccine compositions into several categories as a function of the secretion of specific IL-2 of the protein p24. The best response is induced by the combination MVA+PLA (B), then PLA+MVA (C), PLA alone (D) and MVA alone (A).
-
FIG. 8 shows an appearance kinetics of the specific humoral responses of the protein p24. - All the animals immunised during the 3 successive experiments were included in the analysis.
- For each vaccine composition the number of animals which received this composition is indicated in brackets. The Y axis shows the titre of anti-p24 IgG measured by ELISA for capture of p24; the scale of this axis is logarithmic. The titre of antibodies was determined individually for each mouse. The number presented on this graph corresponds to the geometric mean calculated from all the mice of a group (n=5, 10 or 15 depending upon the groups). S3=
week 3, S6=week 6, S9=week 9. - In so far as the anti-p24 humoral responses are concerned, for the first time in this series of experiments increasing the number of injections makes it possible to significantly improve the measured immune response. For, regardless of the group studied, changing from 2 to 3 injections of immunogen increases the anti-p24 response by approximately 1 log (except for the group of PLA alone where the increase is lower but nevertheless significant).
- For the groups which received 3 injections, all the combinations containing MVA and PLA or PLA alone induce a high titre (10E6) higher by one log than the titre induced by MVA alone.
- In a similar manner, for the groups which received 2 injections, all the compositions containing MVA and PLA or PLA alone induce a high titre, higher by one log than the titre induced by MVA alone.
- Changing an injection of PLA to MVA in a vaccination scheme does not harm the antibody titres but makes it possible to widen the cell responses with respect to those which are generated solely by a PLA vector.
- As a function of the type of response analysed, the best composition is not always the same, as certain compositions specifically obtain very good responses.
- However, in order to obtain a wide and intense immune response, the best composition is the composition PLA+MVA.
- The immunisation experiments were carried out in female BALB/c (H-2Kd) mice aged from 6 to 8 weeks at the time of the first immunisation.
- 2. Immunogens administered
- In this series of experiments the following immunogens were used alone or in combination:
-
- microparticles PLA/p24 prepared according the solvent displacement procedure of Patent Application WO2005/027871.
-
Adenovirus type 5 Gag which is recombinant for the Gag gene of the HIV-1 virus, coding for the protein p24. (Généthon) -
Adenovirus type 5 eGFP which is recombinant for the enhanced Green Fluorescent Protein (Généthon). It is a negative control which serves to measure whether the viral vector induces a non-specific immune response during the immunisations.
- DNA Gag. The Gag gene (SEQ ID No. 1) was cloned in the eukaryotic expression plasmid phCMV (non-commercial plasmid). DNA preparations without endotoxins and in large quantity have been produced with the Gigaprep endotoxin-free kit from Macherey-Nagel. The DNA serves as positive control, since it is known that in mice the administration of naked DNA by the intramuscular route makes it possible to induce a good cytotoxic response (CTL).
- 30 mice received 2 doses of the immunogens described in
point 2 above at 0 to 3 weeks. The vaccine compositions received by each group of mice are indicated in Table 6 below. All the injections were carried out by the intramuscular route for the adenovirus and the DNA and sub-cutaneously for the PLAs. -
TABLE 6 Dose Dose 1st injection 2nd injection Week 0 Week 3Number of mice Composition Ad5 Gag 108 ip Ad5 Gag 108 ip 5 H Ad5 Gag 108 ip PLA/ p24 40 μg5 I PLA/ p24 40μg Ad5 Gag 108 ip 5 J Ad5 Gag 107 ip Ad5 Gag 107 ip 5 H′ Ad5 Gag 107 ipPLA/ p24 40 μg5 I′ PLA/ p24 40μg Ad5 Gag 107 ip 5 J′ - The animals were sacrificed 3 weeks after the last injection and the blood and the spleen were removed for immunological analyses.
- Carried out to the same procedures as in Example 1. Moreover, we have measured the humoral responses directed against the adenovirus5 using an ELISA technique. The procedure is identical to that used for the anti-p24 ELISA, except that an adenovirus lysate is used in capture.
-
FIG. 9 shows the CTL responses obtained during the immunisation experiment No. 2. Each group consist of 5 mice, analysed individually. As the non-specific stimulation (without peptide) in all the groups is 0 it is not shown. The X axis corresponds to the ratio of effector cells (CTL) to target cells (to be lysed). The Y axis corresponds to the mean lysis percentage; this is the arithmetic mean calculated from all the mice of a group (n=5). - In all the
groups 5 mice out of 5 developed a CTL response, except for one mouse of theAd5Gag 107+PLA group. - The same thing is observed for the 2 doses of virus tested: the combinations Ad+Ad (H and H′) and PLA+Ad (J and J′) induce better CTL responses than the combination Ad+PLA (I and I′).
-
FIG. 10 shows the specific ELISPOT IFN-γ responses of the Gag peptide AMQ. The Y axis shows the mean number of cells secreting the IFN-γ in a specific manner in response to a stimulation for 18 hours by the Gag peptide AMQ on one million stimulated cells. This response was determined individually for each mouse (numbered from 1 to 5 for each mouse, thus Hi corresponds to themouse 1 which had received the compositionH Ad5 Gag 108 ip andAd5 Gag 108 ip, etc. The number presented on this graph corresponds to a mean of triplicates. - It may be noted from
FIG. 10 that: -
- at 108: the response PLA+Ad>Ad+Ad>Ad+PLA
- at 107: the response Ad+Ad>PLA+Ad>Ad+PLA. The difference between the compositions Ad+Ad and PLA+Ad is not very clear. Overall the ELISPOT IFN-γ response is in concordance with the CTL test: The compositions PLA+Ad and Ad+Ad are more effective than Ad+PLA.
- As in Example 1, we tested the secretion of 10 cytokines in the supernatant. Amongst these IL-5, IL-6, IL-17 and IFN-γ were not secreted or were secreted at infinitesimal concentrations. As for GM-CSF, TNF-α and IL-1α, their secretion was not specific for the protein p24 by the dosage technique used. It is very probable that it is the immunisation by the adenovirus which causes the secretion of these cytokines. If a specific secretion of the protein p24 exists, it is embedded in that caused by the adenovirus.
- For 3 other cytokines, namely IL-2 (Th1), as well as IL-4 and IL-10 (Th2), we were able to measure the specific secretion of the protein p24. The results are presented in
FIG. 11 . -
FIG. 11 shows the secretion of the cytokines IL-2, IL-4 and IL-10 specific for the protein p24. Each vaccine composition was administered to 5 mice. The cells obtained from mice of one and the same group were pooled before being cultured for the secretion test. The Y axis shows the concentration of each cytokine (in pg/ml) secreted in the culture medium in response to stimulation for 3 days by the protein p24. - The results in
FIG. 11 show that: -
- the composition Ad5 Gag+Ad5 Gag (H and H′) does not give any secretion of IL-2, IL-4 or IL-10.
- only the composition PLA+Ad5 Gag (J and J′) gives a secretion of IL-2 and IL-4.
- the compositions PLA+Ad5 Gag (J and J′) and Ad5 Gag+PLA (I and I′) enable a secretion of IL-10.
- The composition Ad+Ad (H and H′) induces a rather polarised Th1 cytokine response (measured by ELISPOT IFN-γ).
- The composition PLA+Ad 5 (J and J′) induces a non-polarised cytokine response, since not only Th1 cytokines such as IFN-γ (by ELISPOT) and IL-2, but also Th2 cytokines such as IL-4 and IL-10 are detected.
-
FIG. 12 shows the appearance kinetics of the humoral responses.FIG. 12(A) shows the antibody response directed against the protein p24 andFIG. 12(B) shows the antibody response directed against the adenovirus. Each vaccine composition was administered to 5 mice. The Y axis shows the titre of IgG measured by ELISA; the scale of this axis is logarithmic. The titre of antibodies was determined individually for each mouse. The number presented on this graph corresponds to the geometric mean calculated from all the mice of a group (n=5). S3=week 3, S6=week 6. - The anti-adenovirus response (or anti-vector response) is approximately 1 log less in the groups which received the compositions Ad+PLA (I and I′) and PLA+Ad (J and J′) than for Ad+Ad (H and H′).
- The compositions according to the invention therefore make it possible to decrease the anti-adenovirus immunity.
- The immunisation experiments were carried out in female BALB/c (H-2Kd) mice aged from 6 to 8 weeks at the time of the first immunisation.
- In this series of experiments the following immunogens were used alone or in combination:
-
- microparticles PLA/p24 prepared according the solvent displacement procedure of Patent Application WO2005/027871.
- alum/p24: the alum (Imject Alum, Pierce, catalogue No. 77161) is mixed volume for volume (1:1) with the protein p24 diluted in PBS. A dose of 40 μg of p24 is administered per injection and per animal.
- the MVA Gag virus (Modified Vaccinia Virus Ankara, attenuated vaccinia virus, Ankara strain) which is recombinant for the Gag gene of the HIV-1 virus, coding for the protein p24. The recombinant virus was constructed at Transgene, as indicated in Example 1.
- DNA Gag. The Gag gene (SEQ ID No. 1) was cloned in the eukaryotic expression plasmid phCMV. DNA preparations without endotoxins and in large quantity have been produced with the Gigaprep endotoxin-free kit from Macherey-Nagel. The DNA serves as positive control, since it is known that in mice the administration of naked DNA by the intramuscular route makes it possible to induce a good cytotoxic response (CTL).
- 30 mice received 2 doses of the immunogens described in
point 2 above at 0 and 3 weeks. The vaccine compositions received by each group of mice are indicated in Table 7 below. All the injections were carried out subcutaneously except for the DNA which was administered by the intramuscular route. -
TABLE 7 Dose Dose 1st injection 2nd injection Number of Week 0Week 3mice Composition MVA Gag 107 pfu PLA/ p24 40 μg5 B PLA/ p24 40μg MVA Gag 107 pfu 5 C MVA Gag 107 pfu Alum/ p24 40 μg5 K Alum/ p24 40μg MVA Gag 107 pfu 5 L PLA/ p24 40μg DNA Gag 5 μg (IM) 5 G Alum/ p24 40μg DNA Gag 5 μg (IM) 5 M pfu = plaque forming units, this is the unit of measurement of the dose of MVA used. The viral titre is expressed in pfu according to the technique of dosage of the viral stock used. - The animals were sacrificed 6 weeks after the first injection and the blood and the spleen were removed for immunological analyses.
- Carried out according to the same procedures as in Example 1. Moreover, we have measured the humoral responses directed against the MVA using an ELISA technique. The procedure is identical to that used for the anti-p24 ELISA, except that a MVA lysate is used in capture.
-
FIG. 13 shows the specific ELISPOT IFN-γ responses of the Gag peptide AMQ. The Y axis shows the mean number of cells secreting the IFN-γ in a specific manner in response to a stimulation for 18 hours by the Gag peptide AMQ on one million stimulated cells. This response was determined individually for each mouse. The number presented on this graph corresponds to the mean calculated from all the mice in a group (n=5). - The ELISPOT IFN-γ responses obtained during this experiment are lower than usual. This drop is observed both for the tested groups and the control groups, and it is linked to the progress of the experiment. For this reason, as we seek to compare the different combinations with one another, this experiment remains interpretable and shows clearly that the composition PLA/p24+MVA Gag (C) induces a better secretion of IFN-γ measured by ELISPOT than the other groups tested, namely MVA Gag+PLA/p24 (B), MVA Gag+alum/p24 (K), alum/p24+MVA Gag (L).
-
FIG. 14 shows the specific ELISPOT IL-4 responses of the protein p24. The Y axis shows the mean number of cells secreting IFN-γ in a specific manner in response to a stimulation for 42 hours by the protein p24 on a million stimulated cells. This response was determined individually for each mouse. The number presented on this graph corresponds to the calculated mean from all the mice of a group (n=5). - For the induction of a type IL-4 ELISPOT response, the best immunogen consists of the combination MVA Gag and PLA/p24 (B and C). Regardless of the order of administration of this composition, the IL-4 responses obtained are greater than those induced by the compositions MVA Gag+alum/p24 (regardless of the order) (K and L), PLA/p24+DNA Gag (G) and alum/p24+DNA Gag (M). If the order of administration of the products is now considered, it is always the composition PLA/p24+MVA Gag (C) which gives better results than the inverse combination MVA Gag+PLA/p24 (B).
-
FIG. 15 shows an appearance kinetics of the specific humoral responses of the protein p24. The Y axis shows the titre of anti-p24 IgG measured by p24 capture ELISA; the scale of this axis is logarithmic. The titre of antibodies was determined individually for each mouse. The number presented on this graph corresponds to the geometric mean calculated from all the mice of a group (n=5). S2=week 2, S4=week 4, S6=week 6. - For the induction of a specific protein p24 antibody response, the best immunogen again consists of the combination MVA Gag and PLA/p24 (B and C). Regardless of the order of administration of this composition, the titres of anti-P4 IgG obtained are 0.6 to 1.2 log higher at
week 6 than those induced by the compositions MVA Gag+alum/p24 (regardless of the order) (K and L), PLA/p24+DNA Gag (G) and alum/p24+DNA Gag (M). If the order of administration of the products is now considered, it is always the composition PLA/p24+MVA Gag (C) which gives better results than the inverse combination MVA Gag+PLA/p24 (B), but only by 0.4 log. -
FIG. 16 shows the appearance kinetics of the specific humoral responses of the MVA virus. The Y axis shows the titre of anti-MVA IgG measured by ELISA for capture of MVA. The titre of antibodies was determined individually for each mouse. The number presented on this graph corresponds to the geometric mean calculated from all the mice of a group (n=5). S4=week 4, S6=week 6. - In the groups PLA/p24+MVA Gag (C) and alum/p24+MVA Gag (L), the MVA was administered at
week 3. As we can see inFIG. 16 , the anti-MVA response did not have time to become established at the time of the analysis, atweek 6. On the other hand, in the groups which received the MVA injection first it is possible to measure the anti-vector response. Surprisingly, from 4 weeks the anti-MVA response is much lower in the group MVA Gag+PLA/p24 (B) than in the group MVA Gag+alum/p24 (K). Moreover, with the combination MVA Gag+PLA/p24 the anti-MVA titre does not increase in time, which is not the case with the combination MVA Gag+alum/p24. - In association with MVA the PLAs make it possible to limit the anti-MVA antibody response although this is not the case with the combination MVA+alum. This is a very interesting and very useful property for immunisation and vaccination applications.
- The compositions according to the invention PLA/p24 and MVA Gag make it possible to induce better cell and humoral responses than the compositions alum/p24 and MVA Gag. Moreover, they make it possible to limit the anti-vector response.
- The immunisation experiments were carried out in female BALB/c (H-2Kd) mice aged from 6 to 8 weeks at the time of the first immunisation.
- In this series of experiments the following immunogens were used alone or in combination:
-
- microparticles PLA/p24 prepared according the solvent displacement procedure of Patent Application WO2005/027871.
- the MVA Gag virus (Modified Vaccinia Virus Ankara, attenuated vaccinia virus, Ankara strain) which is recombinant for the Gag gene of the HIV-1 virus, coding for the protein p24. The recombinant virus was constructed at Transgene, as indicated previously.
- 10 mice received 3 doses of the immunogens described in
point 2 above at 0, 10 and 20 days. The vaccine compositions received by each group of mice are indicated in Table 8 below. All the injections were carried out intranasally. -
TABLE 8 Dose Dose Dose 1st injection 2nd injection 3rd injection Number Day 0 Day 10Day 20of mice PLA/ p24 20 μgPLA/ p24 20μg MVA Gag 107 pfu 5 MVA Gag 107pfu MVA Gag 107 pfu PLA/ p24 20μg 5 pfu = plaque forming units, this is the unit of measurement of the dose of MVA used. The viral titre is expressed in pfu according to the technique of dosage of the viral stock used. - The animals were sacrificed 32 days after the first injection. The blood, vaginal secretions, faeces, spleen and genital apparatus (vagina) were removed for immunological analyses.
- Carried out according to the same procedures as in Example 1.
- Recapitulation of the experimental data
-
TABLE 9 Vaccine combinations PLA/p24, MVA Gag, PLA/p24, MVA Gag, MVA Gag PLA/p24 Number of mice which developed a CTL 2/5 2/5 response % lysis means of mice CTL+ 50% 45% - The ELISPOT measures the number of cells secreting cytokine per 10E6 cells analysed
-
ELISPOT IFN-γ, AMQ, blood 155 79 ELISPOT IFN-γ, p24, blood 146 94 ELISPOT IL-4, AMQ, blood 50 10 ELISPOT IL-4, p24, blood 126 32 ELISPOT IFN-γ, AMQ, vaginal 1550 754 ELISPOT IL-4, AMQ, vaginal 0 0 ELISPOT IL-4, p24, vaginal 0 0 Titre of anti-p24 IgG of the serum 68 000 200 000 (determined by ELISA) Titre of anti-p24 IgA of the vaginal 18 8 secretions (determined by ELISA) Titre of anti-p24 IgG of the vaginal 124 616 secretions (determined by ELISA) Anti-p24 IgA in the faeces J20 0.20 J20 0.18 (absorbency at 450 nm, J32 0.02 J32 0.03 determined by ELISA) Anti-p24 IgG in the faeces J20 0.17 J20 0.17 (absorbency at 450 nm, J32 0.69 J32 0.60 determined by ELISA) - The intranasal administration of the combinations PLA/p24 and MVA Gag makes it possible to induce both a measured systemic immune response in the taking of blood and spleen, and a peripheral immune response at the mucous level, in particular at the level of the urogenital tract. Each time, the two arms of the immune system are activated: at the level of these two sites it has been possible to demonstrate cell and humoral immune responses directed against the protein p24. The capacity to induce a wide peripheral response at the level of the urogenital tract constitutes a considerable advantage for the combinations PLA/p24 and MVA Gag in the vaccine applications for prophylactic or therapeutic purposes.
- The immunisation experiments were carried out in female BALB/c (H-2Kd) mice aged from 6 to 8 weeks at the time of the first immunisation.
- In this series of experiments the following immunogens were used alone or in combination:
-
- microparticles PLA/beta-gal prepared according the solvent displacement procedure of Patent Application WO2005/027871.
- the MVA beta-gal virus (modified vaccinia virus Ankara, attenuated vaccinia virus, Ankara strain) which is recombinant for the lacZ gene of E. coli, coding for the enzyme beta-galactosidase (beta-gal). The recombinant virus was constructed at Transgene, and produced and purified as described previously.
- 35 mice received 2 doses of the immunogens described in
point 2 above at 0 to 3 weeks. The vaccine compositions received by each group of mice are indicated in Table 10 below. All the injections were carried out subcutaneously. -
TABLE 10 Dose Dose 1st injection 2nd injection Code Week 0 Week 3Number of mice M PLA/beta- gal 40 μgPLA/beta- gal 40 μg5 N MVA beta- gal 107 pfuMVA beta- gal 107 pfu5 O PLA/beta- gal 40 μgMVA beta- gal 107 pfu5 P MVA beta- gal 107 pfuPLA/beta- gal 40 μg5 Q PLA/beta- gal 40 μg +5 MVA beta- gal 107 pfuR PLA/beta- gal 40 μg +5 MVA beta- gal 107 pfuS PLA/beta- gal 40 μg +PLA/beta- gal 40 μg +5 MVA beta- gal 107 pfuMVA beta- gal 107 pfupfu = plaque forming units, this is the unit of measurement of the dose of MVA used. The viral titre is expressed in pfu according to the technique of dosage of the viral stock used. - The animals were sacrificed 6 weeks after the first injection and the blood and the spleen were removed for immunological analyses.
- The humoral response and the cell response were researched as follows:
-
- Cell response: after sacrifice of the mice, the spleens were removed in a sterile manner in order to prepare a cell suspension. ELISPOT makes it possible to determine the number of cells secreting a given cytokine in response to a specific stimulus. We are interested in the cytokines IFN-γ of type Th1. The cell suspensions obtained from the spleens were restimulated in vitro by the peptide TPH (TPHPARIGL—SEQ ID No. 3) for 20 hours in order to analyse the responses of type CD8. The 96-well ELISPOT plates with PVDF membranes (Multiscreen IP, Millipore) were coated by an anti-IFN-γ antibody. During the restimulation the suspensions of splenocytes were incubated in these plates in such a way as to capture the cytokines secreted by each cell. The spots corresponding to each cell secreting the relevant cytokine were revealed by a specific biotinylated detection antibody of the relevant cytokine.
- Humoral response: blood was taken from the mice before they were sacrificed. The presence of anti-beta-gal antibodies was determined by ELISA. The protein beta-gal was used in capture and the specific antibodies present in the serum were revealed by a polyclonal anti-mouse antibody as detection antibody which is an Affinipure goat anti-mouse IgG antibody conjugated with horseradish peroxidase (H+ L, Jackson Immunoresearch, Cat no 115-035-062). The titre is the inverse of the dilution for which an absorbency of 0.1 OD unit is obtained with the ELISA protocol used.
- The results are presented in
FIG. 17 which shows the specific ELISPOT IFN-γ responses of the beta-gal peptide TPH. The Y axis shows the mean number of cells secreting IFN-γ in a specific manner in response to a stimulation for 18 hours by the beta-gal peptide TPH on one million stimulated cells. This response was determined individually for each mouse. The number presented on this graph corresponds to the mean calculated from all the mice in a group (n=5). - These results demonstrate that it is possible to classify the vaccine combinations into several categories as a function of the ELISPOT IFN-γ responses obtained. The best responses are induced by the combinations PLA+MVA in separate injections (O) or two simultaneous injections (S). Intermediate responses are obtained with one single injection of PLA+MVA at the same time (groups Q and R). The lower responses are observed with the groups only containing one single immunogen PLA alone (M) or MVA alone (N).
- Thus also in the beta-galactosidase we have been able to show that the vaccine combination PLA+MVA was better than the combination MVA+MVA for inducing a secretion of specific IFN-γ of the peptide TPH. Moreover, the order of injection also seems to be important because amongst all the combinations PLA+MVA tested it is the
group 0, PLA then MVA, which made it possible to obtain the best result. It should be noted that it is also the same combination which was shown to be most effective in the p24 model (Example 1). - The results are presented in
FIG. 18 which compares the appearance kinetics of the specific humoral responses of the protein beta-gal. The Y axis shows the titre of anti-beta-gal IgG measured by beta-gal capture ELISA; the scale of this axis is logarithmic. The titre of antibodies was determined individually for each mouse. The number presented on this graph corresponds to the mean calculated from all the mice of a group (n=5). S3=week 2,S6 week 6. - These results show that the best humoral responses are obtained for the group PLA+PLA (M). The titres induced in mice which received PLA and MVA at each injection (S) are comparable. In the
groups 0, P, Q and R the titres are lower by approximately one log. Amongst all the combinations tested, the poorest inducer of anti-beta-gal antibodies is MVA+MVA. In the beta-galactosidase model, as in the p24 model, all the combinations containing MVA and PLA induce a high titre, higher by one log than the titre induced by MVA alone. - As in Example 1 (p24) changing an injection from PLA to MVA in a vaccination scheme does not to much harm to the titres of antibodies obtained but makes it possible to widen the cell responses with respect to those which are generated solely by a PLA vector.
- Even if the PLA+MVA (S) immunisation does not make it possible to induce the best immune response according to each type of response analysed, overall it is the group for which the widest and most intense responses are observed.
- The immunisation experiments were carried out in female BALB/c (H-2Kd) mice aged from 6 to 8 weeks at the time of the first immunisation.
- In this series of experiments the following immunogens were used alone or in combination:
-
- the CPL microparticles used in this work are formed by coprecipitation of two polysaccharides; chitosan (Mahtani chitosan PVT Batch 124) and dextran sulphate (Sigma: 31404). The two polymers are previously dissolved in water at
pH 4 containing 50 mM of NaCl. The solutions are left with magnetic agitation for 12 hours before preparation of the particles. Then 20 ml of the 0.1% chitosan solution (molar mass of 105000 g/mol and a degree of acetylation 9) are mixed with 9.35 ml of the 0.1% dextran sulphate solution. The deficient solution is poured rapidly onto the excess solution which is agitated magnetically at 1000 rpm. The mixture is left for 30 seconds on the agitator at 500 rpm, then it is centrifuged for 30 minutes at 7800 g. The supernatant is eliminated by reversal, the residue is taken up in water then centrifuged again for 30 minutes at 8000 g. The residues thus obtained are taken up in water and kept at ambient temperature with constant agitation. The particles obtained are characterised by a measurement of size (Coulter granulometer) and of charge (Malvern Zetasizer). - For the adsorption of the protein p24 on the CPLs, the p24 at 1 g/l in
phosphate buffer 10 mM pH 5.7 is mixed volume for volume with CPL particles with 1% solids, that is to say final 0.5%. The samples are agitated on a wheel at ambient temperature for 20 hours. After incubation the tubes are recovered and centrifuged for 10 minutes at 1800 g at 20° C. The supernatants are recovered and centrifuged for 15 minutes at 3000 g at 20° C. to eliminate the particles which may remain in suspension, then the protein concentration is determined using a BCA dosage (BCA Protein Assay kit, Pierce: 23225). The residues are taken up in 400 μl of 10 mM phosphate buffer. The particles obtained are characterised by a measurement of size and charge. - the MVA Gag virus (Modified Vaccinia Virus Ankara, attenuated vaccinia virus, Ankara strain) which is recombinant for the Gag gene of the HIV-1 virus, coding for the protein p24. The recombinant virus was constructed at Transgene, and produced and purified as described above.
- the CPL microparticles used in this work are formed by coprecipitation of two polysaccharides; chitosan (Mahtani chitosan PVT Batch 124) and dextran sulphate (Sigma: 31404). The two polymers are previously dissolved in water at
- 35 mice received 2 doses of the immunogens described in
point 2 above at 0 to 3 weeks. The vaccine combinations received by each group of mice are indicated in Table 11 below. All the injections were carried out subcutaneously. -
TABLE 11 Dose Dose 1st injection 2nd injection Code Week 0 Week 3Number of mice T CPL/ p24 10 μgCPL/ p24 10 μg5 U MVA Gag 107 pfu MVA Gag 107 pfu 5 V CPL/ p24 10μg MVA Gag 107 pfu 5 W MVA Gag 107 pfu CPL/ p24 10 μg5 X CPL/ p24 10 μg +5 MVA Gag 107 pfuY CPL/ p24 10 μg +5 MVA Gag 107 pfuZ CPL/ p24 10 μg +CPL/ p24 10 μg +5 MVA Gag 107pfu MVA Gag 107 pfu pfu = plaque forming units, this is the unit of measurement of the dose of MVA used. The viral titre is expressed in pfu according to the technique of dosage of the viral stock used. - The animals were sacrificed 6 weeks after the first injection and the blood and the spleen were removed for immunological analyses.
- Carried out according to the same procedures as in Example 1.
- The results are presented in
FIG. 19 which shows the specific ELISPOT IFN-γ responses of the p24 peptide AMQ. The Y axis shows the mean number of cells secreting IFN-γ in a specific manner in response to a stimulation for 18 hours by the p24 peptide AMQ on one million stimulated cells. This response was determined individually for each mouse. The number presented on this graph corresponds to the mean calculated from all the mice in a group (n=5). - These results show that it is possible to classify the vaccine combinations into several categories as a function of the ELISPOT IFN-γ responses obtained. The best response is induced by the combination MVA+MVA (U). The second category contains the combinations CPL+MVA in separate injections (V) or two simultaneous injections (Z). One single simultaneous injection of CPL and MVA (X and Y) is not effective enough to induce a high ELISPOT IFN-γ response. Finally, the combination CPL+CPL (T) is the less effective.
- As for the combination PLA+MVA, the combination CPL+MVA is effective for inducing a secretion of specific IFN-γ of the peptide AMQ. However, the simultaneous injection of the two immunogens does not make it possible to improve performances with respect to administration separated by 3 weeks (Z vs V).
- The results are presented in
FIG. 20 which compares the appearance kinetics of the specific humoral responses of the protein p24. The Y axis shows the titre of anti-p24 IgG measured by ELISA for capture of p24; the scale of this axis is logarithmic. The titre of antibodies was determined individually for each mouse. The number presented on this graph corresponds to the mean calculated from all the mice of a group (n=5). S3=week 2, S6=week 6. - These results show that for the groups which received 2 injections all the combinations containing CPL and MVA (V, W, Z) or CPL alone (T) induce a high titre (10E6), higher by 2-3 log than the titre induced by MVA alone. However, the combination CPL+MVA (V) is more effective than the inverse order of injection (W). In the groups which received only one single injection of CPL and MVA (X and Y), the titres of antibodies are lower, but nevertheless higher than what is obtained with MVA alone.
- As for the combination PLA+MVA, changing an injection from CPL to MVA in a vaccination scheme does not harm the titres of antibodies obtained but makes it possible to considerably increase the cell responses with respect to those which are generated solely by a CPL vector.
- All of the examples enable us to show that the combination of a colloidal synthetic bioresorbable vector, such as PLA, CPL, and a viral vector, such as MVA and adenovirus, makes it possible to induce effective and wide immune responses. To be most effective, the combination should preferably be administered in the order synthetic vector, then viral vector.
Claims (18)
1. Pharmaceutical composition comprising
a colloidal synthetic bioresorbable vector comprising at least one protein substance, and
a viral vector comprising at least one nucleotide sequence which codes for a protein substance corresponding to at least one protein substance of the synthetic vector.
2. Composition according to claim 1 , wherein it comprises a vector of spherical nature as the colloidal synthetic vector.
3. Composition according to claim 1 , wherein the colloidal synthetic vector is prepared from at least one polymer chosen from amongst the poly(α-hydroxy acids).
4. Composition according to claim 1 , wherein the colloidal synthetic vector is prepared from at least one natural polymer.
5. Composition according to claim 1 , wherein the colloidal synthetic vector comprises protein substances of different types, each constituting an antigen associated with the same disease.
6. Composition according to the claim 1 , wherein it comprises an adenovirus or a poxvirus as the viral vector.
7. Composition according to claim 6 , wherein the poxvirus is the Modified Vaccinia Virus Ankara.
8. Composition according to claim 1 , wherein the protein substances are of viral origin.
9. Composition according to claim 8 , wherein the protein substances of viral origin are proteins of the HIV virus.
10. Composition according to claim 1 , wherein the protein substance is an antigen associated with tumours.
11. A method for preparing a medicament, comprising:
utilizing the composition of claim 1 .
12. A method for preparing a vaccine, comprising:
utilizing the composition of claim 1 .
13. A method for diagnosing in vitro of the pathological state for which the protein substance or substances of the synthetic vector a constitute antigens, comprising:
utilizing the composition of claim 1 .
14. The method according to claim 13 , wherein the pathological state is a viral infection.
15. The method according to claim 13 , wherein the pathological state is a cancer.
16. Method of prophylactic or therapeutic treatment, in particular vaccination, comprising the administration to a patient of an effective dose of the composition as defined in claim 1 .
17. Method of treatment according to claim 16 , wherein the composition is administered in a staggered manner.
18. Method of treatment according to claim 17 , wherein the synthetic vector is administered before the viral vector.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0553445 | 2005-11-14 | ||
FR0553445A FR2893254B1 (en) | 2005-11-14 | 2005-11-14 | COMPOSITION COMPRISING A BIORESORBABLE COLLOIDAL SYNTHETIC VECTOR AND A VIRAL VECTOR AND ITS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC USE. |
PCT/FR2006/051039 WO2007057582A1 (en) | 2005-11-14 | 2006-10-17 | Composition comprising a colloidal synthetic bioresorbable vector and a viral vector |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2006/051039 A-371-Of-International WO2007057582A1 (en) | 2005-11-14 | 2006-10-17 | Composition comprising a colloidal synthetic bioresorbable vector and a viral vector |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/620,920 Division US9433674B2 (en) | 2005-11-14 | 2015-02-12 | Composition comprising a colloidal synthetic bioresorbable vector and a viral vector |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090123493A1 true US20090123493A1 (en) | 2009-05-14 |
Family
ID=36649740
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/084,970 Abandoned US20090123493A1 (en) | 2005-11-14 | 2006-10-17 | Composition Comprising a Colloidal Synthetic Bioresorbable Vector and a Viral Vector |
US14/620,920 Active US9433674B2 (en) | 2005-11-14 | 2015-02-12 | Composition comprising a colloidal synthetic bioresorbable vector and a viral vector |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/620,920 Active US9433674B2 (en) | 2005-11-14 | 2015-02-12 | Composition comprising a colloidal synthetic bioresorbable vector and a viral vector |
Country Status (9)
Country | Link |
---|---|
US (2) | US20090123493A1 (en) |
EP (1) | EP1948231B1 (en) |
JP (1) | JP5524486B2 (en) |
AT (1) | ATE491469T1 (en) |
CA (1) | CA2630530C (en) |
DE (1) | DE602006018985D1 (en) |
ES (1) | ES2355943T3 (en) |
FR (1) | FR2893254B1 (en) |
WO (1) | WO2007057582A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8802433B2 (en) | 2009-12-03 | 2014-08-12 | Aureo Co., Ltd. | Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US6099831A (en) * | 1992-09-25 | 2000-08-08 | Centre National De La Recherche Scientifique | Viral recombinant vectors for expression in muscle cells |
US20070059681A1 (en) * | 2003-09-22 | 2007-03-15 | Biomerieux | Method for production of bioresorable microparticles, microparticles thus obtained and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE235890T1 (en) * | 1997-01-30 | 2003-04-15 | Chiron Corp | USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE DEFENSE |
GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
GB9726555D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
US6824793B1 (en) * | 1998-06-01 | 2004-11-30 | Chiron Corporation | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
ES2260291T3 (en) | 2000-09-28 | 2006-11-01 | Chiron Corporation | MICROPARTICLES FOR THE ADMINISTRATION OF HETEROLOGICAL NUCLEIC ACIDS. |
WO2002034287A2 (en) * | 2000-10-27 | 2002-05-02 | Pharmexa A/S | Therapeutic vaccine formulations containing chitosan |
CA2454959C (en) * | 2001-03-08 | 2018-07-10 | Bernard Moss | Mva expressing modified hiv envelope, gag, and pol genes |
-
2005
- 2005-11-14 FR FR0553445A patent/FR2893254B1/en not_active Expired - Fee Related
-
2006
- 2006-10-17 AT AT06820300T patent/ATE491469T1/en not_active IP Right Cessation
- 2006-10-17 EP EP06820300A patent/EP1948231B1/en active Active
- 2006-10-17 US US12/084,970 patent/US20090123493A1/en not_active Abandoned
- 2006-10-17 WO PCT/FR2006/051039 patent/WO2007057582A1/en active Application Filing
- 2006-10-17 JP JP2008539473A patent/JP5524486B2/en active Active
- 2006-10-17 CA CA2630530A patent/CA2630530C/en not_active Expired - Fee Related
- 2006-10-17 ES ES06820300T patent/ES2355943T3/en active Active
- 2006-10-17 DE DE602006018985T patent/DE602006018985D1/en active Active
-
2015
- 2015-02-12 US US14/620,920 patent/US9433674B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US6099831A (en) * | 1992-09-25 | 2000-08-08 | Centre National De La Recherche Scientifique | Viral recombinant vectors for expression in muscle cells |
US20070059681A1 (en) * | 2003-09-22 | 2007-03-15 | Biomerieux | Method for production of bioresorable microparticles, microparticles thus obtained and use thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8802433B2 (en) | 2009-12-03 | 2014-08-12 | Aureo Co., Ltd. | Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages |
Also Published As
Publication number | Publication date |
---|---|
CA2630530A1 (en) | 2007-05-24 |
FR2893254A1 (en) | 2007-05-18 |
DE602006018985D1 (en) | 2011-01-27 |
FR2893254B1 (en) | 2007-12-21 |
EP1948231B1 (en) | 2010-12-15 |
WO2007057582A1 (en) | 2007-05-24 |
ES2355943T3 (en) | 2011-04-01 |
JP5524486B2 (en) | 2014-06-18 |
ATE491469T1 (en) | 2011-01-15 |
US20150150967A1 (en) | 2015-06-04 |
EP1948231A1 (en) | 2008-07-30 |
US9433674B2 (en) | 2016-09-06 |
JP2009515859A (en) | 2009-04-16 |
CA2630530C (en) | 2016-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7097843B2 (en) | Immunogenic peptides from the HPV E7 protein | |
Okada et al. | Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. | |
RU2129439C1 (en) | Antigenic composition for inducing cytotoxic t-lymphocytes response, method of induction and method of patients treatment | |
AP661A (en) | Induction of cytotoxic T- lymphocite responses. | |
CN1262665C (en) | Codon-optimized papilloma virus sequences | |
JP2002508333A (en) | vaccine | |
US11638753B2 (en) | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy | |
AU9799298A (en) | Immunogenic peptides from the hpv e7 protein | |
TW201938793A (en) | A novel vaccine adjuvant | |
US9433674B2 (en) | Composition comprising a colloidal synthetic bioresorbable vector and a viral vector | |
WO2004052395A1 (en) | L2-peptide of the human papillomavirus associated with virus-like particles | |
WO2023280303A1 (en) | Use of avc-29 as vaccine adjuvant and vaccine composition containing adjuvant | |
WO2023184862A1 (en) | Hpv epitope, identification method therefor, and application thereof | |
US20070275071A1 (en) | Use of Microparticles for Antigen Delivery | |
JP6152944B2 (en) | Bound immunogenic composition and uses thereof | |
CN100393878C (en) | Vaccine | |
US20110287089A1 (en) | Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation | |
US20110064769A1 (en) | Vv promoter-driven overexpression of recombinant antigens | |
KR100478617B1 (en) | Induction of cytotoxic t-lymphocyte responses | |
KR20040006196A (en) | Composition of genetic adjuvants comprising cationic polymer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ATAMAN-ONAL, YASEMIN;DELAIR, THIERRY;VERRIER, BERNARD;REEL/FRAME:023725/0675;SIGNING DATES FROM 20080603 TO 20091110 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |